<?xml version="1.0" encoding="UTF-8"?>
<OAI-PMH xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="http://www.openarchives.org/OAI/2.0/ http://www.openarchives.org/OAI/2.0/OAI-PMH.xsd">
  <responseDate>2024-05-03T11:05:11Z</responseDate>
  <request verb="GetRecord" identifier="oai:pubmedcentral.nih.gov:6224605" metadataPrefix="pmc">https:/www.ncbi.nlm.nih.gov/pmc/oai/oai.cgi</request>
  <GetRecord>
    <record>
      <header>
        <identifier>oai:pubmedcentral.nih.gov:6224605</identifier>
        <datestamp>2018-11-13</datestamp>
        <setSpec>elsevierwt</setSpec>
        <setSpec>pmc-open</setSpec>
      </header>
      <metadata>
        <article xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:ali="http://www.niso.org/schemas/ali/1.0/" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" xsi:schemaLocation="https://jats.nlm.nih.gov/ns/archiving/1.3/ https://jats.nlm.nih.gov/archiving/1.3/xsd/JATS-archivearticle1-3.xsd" article-type="research-article">
          <front>
            <journal-meta>
              <journal-id journal-id-type="nlm-ta">Cell Metab</journal-id>
              <journal-id journal-id-type="iso-abbrev">Cell Metab</journal-id>
              <journal-title-group>
                <journal-title>Cell Metabolism</journal-title>
              </journal-title-group>
              <issn pub-type="ppub">1550-4131</issn>
              <issn pub-type="epub">1932-7420</issn>
              <publisher>
                <publisher-name>Cell Press</publisher-name>
              </publisher>
            </journal-meta>
            <article-meta>
              <article-id pub-id-type="accession">PMC6224605</article-id>
              <article-id pub-id-type="pmcid">PMC6224605</article-id>
              <article-id pub-id-type="pmc-uid">6224605</article-id>
              <article-id pub-id-type="pmid">30244975</article-id>
              <article-id pub-id-type="publisher-id">S1550-4131(18)30522-9</article-id>
              <article-id pub-id-type="doi">10.1016/j.cmet.2018.08.021</article-id>
              <article-categories>
                <subj-group subj-group-type="heading">
                  <subject>Article</subject>
                </subj-group>
              </article-categories>
              <title-group>
                <article-title>Integrated Pharmacodynamic Analysis Identifies Two Metabolic Adaption Pathways to Metformin in Breast Cancer</article-title>
              </title-group>
              <contrib-group>
                <contrib contrib-type="author">
                  <name>
                    <surname>Lord</surname>
                    <given-names>Simon R.</given-names>
                  </name>
                  <email>simon.lord@oncology.ox.ac.uk</email>
                  <xref rid="aff1" ref-type="aff">1</xref>
                  <xref rid="aff2" ref-type="aff">2</xref>
                  <xref rid="aff3" ref-type="aff">3</xref>
                  <xref rid="fn2" ref-type="fn">21</xref>
                  <xref rid="cor1" ref-type="corresp">∗</xref>
                </contrib>
                <contrib contrib-type="author">
                  <name>
                    <surname>Cheng</surname>
                    <given-names>Wei-Chen</given-names>
                  </name>
                  <xref rid="aff1" ref-type="aff">1</xref>
                </contrib>
                <contrib contrib-type="author">
                  <name>
                    <surname>Liu</surname>
                    <given-names>Dan</given-names>
                  </name>
                  <xref rid="aff1" ref-type="aff">1</xref>
                </contrib>
                <contrib contrib-type="author">
                  <name>
                    <surname>Gaude</surname>
                    <given-names>Edoardo</given-names>
                  </name>
                  <xref rid="aff4" ref-type="aff">4</xref>
                </contrib>
                <contrib contrib-type="author">
                  <name>
                    <surname>Haider</surname>
                    <given-names>Syed</given-names>
                  </name>
                  <xref rid="aff5" ref-type="aff">5</xref>
                </contrib>
                <contrib contrib-type="author">
                  <name>
                    <surname>Metcalf</surname>
                    <given-names>Tom</given-names>
                  </name>
                  <xref rid="aff6" ref-type="aff">6</xref>
                </contrib>
                <contrib contrib-type="author">
                  <name>
                    <surname>Patel</surname>
                    <given-names>Neel</given-names>
                  </name>
                  <xref rid="aff7" ref-type="aff">7</xref>
                </contrib>
                <contrib contrib-type="author">
                  <name>
                    <surname>Teoh</surname>
                    <given-names>Eugene J.</given-names>
                  </name>
                  <xref rid="aff1" ref-type="aff">1</xref>
                  <xref rid="aff2" ref-type="aff">2</xref>
                  <xref rid="aff7" ref-type="aff">7</xref>
                </contrib>
                <contrib contrib-type="author">
                  <name>
                    <surname>Gleeson</surname>
                    <given-names>Fergus</given-names>
                  </name>
                  <xref rid="aff1" ref-type="aff">1</xref>
                  <xref rid="aff3" ref-type="aff">3</xref>
                  <xref rid="aff7" ref-type="aff">7</xref>
                </contrib>
                <contrib contrib-type="author">
                  <name>
                    <surname>Bradley</surname>
                    <given-names>Kevin</given-names>
                  </name>
                  <xref rid="aff7" ref-type="aff">7</xref>
                </contrib>
                <contrib contrib-type="author">
                  <name>
                    <surname>Wigfield</surname>
                    <given-names>Simon</given-names>
                  </name>
                  <xref rid="aff2" ref-type="aff">2</xref>
                </contrib>
                <contrib contrib-type="author">
                  <name>
                    <surname>Zois</surname>
                    <given-names>Christos</given-names>
                  </name>
                  <xref rid="aff2" ref-type="aff">2</xref>
                </contrib>
                <contrib contrib-type="author">
                  <name>
                    <surname>McGowan</surname>
                    <given-names>Daniel R.</given-names>
                  </name>
                  <xref rid="aff1" ref-type="aff">1</xref>
                </contrib>
                <contrib contrib-type="author">
                  <name>
                    <surname>Ah-See</surname>
                    <given-names>Mei-Lin</given-names>
                  </name>
                  <xref rid="aff8" ref-type="aff">8</xref>
                </contrib>
                <contrib contrib-type="author">
                  <name>
                    <surname>Thompson</surname>
                    <given-names>Alastair M.</given-names>
                  </name>
                  <xref rid="aff9" ref-type="aff">9</xref>
                </contrib>
                <contrib contrib-type="author">
                  <name>
                    <surname>Sharma</surname>
                    <given-names>Anand</given-names>
                  </name>
                  <xref rid="aff1" ref-type="aff">1</xref>
                  <xref rid="aff2" ref-type="aff">2</xref>
                </contrib>
                <contrib contrib-type="author">
                  <name>
                    <surname>Bidaut</surname>
                    <given-names>Luc</given-names>
                  </name>
                  <xref rid="aff10" ref-type="aff">10</xref>
                  <xref rid="aff11" ref-type="aff">11</xref>
                </contrib>
                <contrib contrib-type="author">
                  <name>
                    <surname>Pollak</surname>
                    <given-names>Michael</given-names>
                  </name>
                  <xref rid="aff12" ref-type="aff">12</xref>
                </contrib>
                <contrib contrib-type="author">
                  <name>
                    <surname>Roy</surname>
                    <given-names>Pankaj G.</given-names>
                  </name>
                  <xref rid="aff13" ref-type="aff">13</xref>
                </contrib>
                <contrib contrib-type="author">
                  <name>
                    <surname>Karpe</surname>
                    <given-names>Fredrik</given-names>
                  </name>
                  <xref rid="aff14" ref-type="aff">14</xref>
                </contrib>
                <contrib contrib-type="author">
                  <name>
                    <surname>James</surname>
                    <given-names>Tim</given-names>
                  </name>
                  <xref rid="aff15" ref-type="aff">15</xref>
                </contrib>
                <contrib contrib-type="author">
                  <name>
                    <surname>English</surname>
                    <given-names>Ruth</given-names>
                  </name>
                  <xref rid="aff16" ref-type="aff">16</xref>
                </contrib>
                <contrib contrib-type="author">
                  <name>
                    <surname>Adams</surname>
                    <given-names>Rosie F.</given-names>
                  </name>
                  <xref rid="aff16" ref-type="aff">16</xref>
                </contrib>
                <contrib contrib-type="author">
                  <name>
                    <surname>Campo</surname>
                    <given-names>Leticia</given-names>
                  </name>
                  <xref rid="aff1" ref-type="aff">1</xref>
                </contrib>
                <contrib contrib-type="author">
                  <name>
                    <surname>Ayers</surname>
                    <given-names>Lisa</given-names>
                  </name>
                  <xref rid="aff17" ref-type="aff">17</xref>
                </contrib>
                <contrib contrib-type="author">
                  <name>
                    <surname>Snell</surname>
                    <given-names>Cameron</given-names>
                  </name>
                  <xref rid="aff18" ref-type="aff">18</xref>
                </contrib>
                <contrib contrib-type="author">
                  <name>
                    <surname>Roxanis</surname>
                    <given-names>Ioannis</given-names>
                  </name>
                  <xref rid="aff19" ref-type="aff">19</xref>
                </contrib>
                <contrib contrib-type="author">
                  <name>
                    <surname>Frezza</surname>
                    <given-names>Christian</given-names>
                  </name>
                  <xref rid="aff4" ref-type="aff">4</xref>
                  <xref rid="fn1" ref-type="fn">20</xref>
                </contrib>
                <contrib contrib-type="author">
                  <name>
                    <surname>Fenwick</surname>
                    <given-names>John D.</given-names>
                  </name>
                  <xref rid="aff6" ref-type="aff">6</xref>
                  <xref rid="fn1" ref-type="fn">20</xref>
                </contrib>
                <contrib contrib-type="author">
                  <name>
                    <surname>Buffa</surname>
                    <given-names>Francesca M.</given-names>
                  </name>
                  <xref rid="aff1" ref-type="aff">1</xref>
                  <xref rid="fn1" ref-type="fn">20</xref>
                </contrib>
                <contrib contrib-type="author">
                  <name>
                    <surname>Harris</surname>
                    <given-names>Adrian L.</given-names>
                  </name>
                  <xref rid="aff1" ref-type="aff">1</xref>
                  <xref rid="aff2" ref-type="aff">2</xref>
                  <xref rid="aff3" ref-type="aff">3</xref>
                  <xref rid="fn1" ref-type="fn">20</xref>
                </contrib>
              </contrib-group>
              <aff id="aff1"><label>1</label>Department of Oncology, University of Oxford, Churchill Hospital, Oxford OX3 7LE, UK</aff>
              <aff id="aff2"><label>2</label>Molecular Oncology Laboratories, Weatherall Institute of Molecular Medicine, University of Oxford, John Radcliffe Hospital, Oxford OX3 9DS, UK</aff>
              <aff id="aff3"><label>3</label>NIHR Oxford Biomedical Research Centre, Oxford University Hospitals NHS Foundation Trust, Churchill Hospital, Oxford OX3 7LE, UK</aff>
              <aff id="aff4"><label>4</label>MRC Cancer Unit, University of Cambridge, Hutchison/MRC Research Centre, Cambridge Biomedical Campus, Cambridge CB2 0XZ, UK</aff>
              <aff id="aff5"><label>5</label>Breast Cancer Now Research Centre, The Institute of Cancer Research, London SW3 6JB, UK</aff>
              <aff id="aff6"><label>6</label>Institute of Translational Medicine, University of Liverpool, Royal Liverpool University Hospital, Liverpool L69 3GA, UK</aff>
              <aff id="aff7"><label>7</label>Department of Nuclear Medicine, Oxford University Hospitals NHS Foundation Trust, Churchill Hospital, Oxford OX3 7LE, UK</aff>
              <aff id="aff8"><label>8</label>Department of Oncology, Luton and Dunstable Hospital, Luton, UK</aff>
              <aff id="aff9"><label>9</label>Department of Breast Surgical Oncology, MD Anderson Cancer Centre, Houston, TX 77030, USA</aff>
              <aff id="aff10"><label>10</label>College of Science, University of Lincoln, Lincoln LN6 7TS, UK</aff>
              <aff id="aff11"><label>11</label>Clinical Research Imaging Facility, University of Dundee, Ninewells Hospital, Dundee DD2 1SY, UK</aff>
              <aff id="aff12"><label>12</label>Department of Oncology, McGill University, Montreal, QC H3T 1E2, Canada</aff>
              <aff id="aff13"><label>13</label>Breast Surgery Unit, Oxford University Hospitals NHS Foundation Trust, Churchill Hospital, Oxford OX3 7LE, UK</aff>
              <aff id="aff14"><label>14</label>Oxford Centre for Diabetes, Endocrinology and Metabolism, Radcliffe Department of Medicine, University of Oxford, Churchill Hospital, Oxford OX3 7LE, UK</aff>
              <aff id="aff15"><label>15</label>Department of Clinical Biochemistry, Oxford University Hospitals NHS Foundation Trust, John Radcliffe Hospital, Oxford OX3 9DU, UK</aff>
              <aff id="aff16"><label>16</label>Oxford Breast Imaging Centre, Oxford University Hospitals NHS Foundation Trust, Oxford OX3 7LE, UK</aff>
              <aff id="aff17"><label>17</label>Department of Clinical and Laboratory Immunology, Oxford University Hospitals NHS Foundation Trust, Churchill Hospital, Oxford OX3 7LE, UK</aff>
              <aff id="aff18"><label>18</label>Department of Anatomical Pathology, Mater Research Institute, Brisbane 4101, Australia</aff>
              <aff id="aff19"><label>19</label>Department of Cellular Pathology, Oxford University Hospitals NHS Foundation Trust, John Radcliffe Hospital, Oxford OX3 9DU, UK</aff>
              <author-notes>
                <corresp id="cor1"><label>∗</label>Corresponding author <email>simon.lord@oncology.ox.ac.uk</email></corresp>
                <fn id="fn1">
                  <label>20</label>
                  <p id="ntpara0010">These authors contributed equally</p>
                </fn>
                <fn id="fn2">
                  <label>21</label>
                  <p id="ntpara0015">Lead Contact</p>
                </fn>
              </author-notes>
              <pub-date pub-type="pmc-release">
                <day>06</day>
                <month>11</month>
                <year>2018</year>
              </pub-date>
              <!-- PMC Release delay is 0 months and 0 days and was based on <pub-date
						pub-type="ppub">.-->
              <pub-date pub-type="ppub">
                <day>06</day>
                <month>11</month>
                <year>2018</year>
              </pub-date>
              <volume>28</volume>
              <issue>5</issue>
              <fpage>679</fpage>
              <lpage>688.e4</lpage>
              <history>
                <date date-type="received">
                  <day>7</day>
                  <month>10</month>
                  <year>2017</year>
                </date>
                <date date-type="rev-recd">
                  <day>21</day>
                  <month>4</month>
                  <year>2018</year>
                </date>
                <date date-type="accepted">
                  <day>24</day>
                  <month>8</month>
                  <year>2018</year>
                </date>
              </history>
              <permissions>
                <copyright-statement>Crown Copyright © 2018 Published by Elsevier Inc. All rights reserved.</copyright-statement>
                <copyright-year>2018</copyright-year>
                <copyright-holder/>
                <license license-type="CC BY" xlink:href="http://creativecommons.org/licenses/by/4.0/">
                  <license-p>This is an open access article under the CC BY license (http://creativecommons.org/licenses/by/4.0/).</license-p>
                </license>
              </permissions>
              <abstract id="abs0010">
                <title>Summary</title>
                <p>Late-phase clinical trials investigating metformin as a cancer therapy are underway. However, there remains controversy as to the mode of action of metformin in tumors at clinical doses. We conducted a clinical study integrating measurement of markers of systemic metabolism, dynamic FDG-PET-CT, transcriptomics, and metabolomics at paired time points to profile the bioactivity of metformin in primary breast cancer. We show metformin reduces the levels of mitochondrial metabolites, activates multiple mitochondrial metabolic pathways, and increases 18-FDG flux in tumors. Two tumor groups are identified with distinct metabolic responses, an OXPHOS transcriptional response (OTR) group for which there is an increase in OXPHOS gene transcription and an FDG response group with increased 18-FDG uptake. Increase in proliferation, as measured by a validated proliferation signature, suggested that patients in the OTR group were resistant to metformin treatment. We conclude that mitochondrial response to metformin in primary breast cancer may define anti-tumor effect.</p>
              </abstract>
              <abstract abstract-type="graphical" id="abs0015">
                <title>Graphical Abstract</title>
                <fig id="undfig1" position="anchor">
                  <graphic xlink:href="fx1"/>
                </fig>
              </abstract>
              <abstract abstract-type="author-highlights" id="abs0020">
                <title>Highlights</title>
                <p>
                  <list list-type="simple" id="ulist0010">
                    <list-item id="u0010">
                      <label>•</label>
                      <p id="p0010">A pharmacodynamic window study of metformin in patients with breast cancer</p>
                    </list-item>
                    <list-item id="u0015">
                      <label>•</label>
                      <p id="p0015">Metformin increases 18-FDG flux in primary breast cancer</p>
                    </list-item>
                    <list-item id="u0020">
                      <label>•</label>
                      <p id="p0020">Two distinct metabolic responses to metformin are identified in tumors</p>
                    </list-item>
                    <list-item id="u0025">
                      <label>•</label>
                      <p id="p0025">Tumors that upregulate OXPHOS genes show an increase in proliferation score</p>
                    </list-item>
                  </list>
                </p>
              </abstract>
              <abstract abstract-type="teaser" id="abs0025">
                <p>Using dynamic PET imaging, metabolomics, and transcriptomics in breast cancer patients, Lord et al. find that metformin increases 18-FDG flux into tumors and activates mitochondrial metabolism genes. Two distinct metabolic responses are observed and linked to differing proliferation signatures, suggesting that a reactive increase in OXPHOS is linked to metformin resistance.</p>
              </abstract>
              <kwd-group id="kwrds0010">
                <title>Keywords</title>
                <kwd>metformin</kwd>
                <kwd>breast neoplasms</kwd>
                <kwd>positron emission tomography</kwd>
                <kwd>gene expression profiling</kwd>
                <kwd>metabolomics</kwd>
                <kwd>mitochondria</kwd>
                <kwd>cancer metabolism</kwd>
                <kwd>clinical study</kwd>
              </kwd-group>
            </article-meta>
            <notes>
              <p id="misc0010">Published: September 20, 2018</p>
            </notes>
          </front>
          <body>
            <sec id="sec1">
              <title>Introduction</title>
              <p id="p0030">Metformin can reduce proliferation of cancer cell lines <italic>in vitro</italic> and <italic>in vivo</italic>, and this effect has been ascribed to inhibition of mitochondrial complex 1 (<xref rid="bib38" ref-type="bibr">Wheaton et al., 2014</xref>). However, the doses of metformin used have typically been 10- to 1,000-fold greater than peak plasma level in humans (<xref rid="bib14" ref-type="bibr">Dowling et al., 2012</xref>). Hence controversy remains as to whether metformin's effects on tumor metabolism at clinical doses are determined by its direct effects on mitochondria or through its action on systemic metabolism via AMPK-dependent inhibition of hepatic gluconeogenesis and subsequent reduced circulating glucose and insulin levels.</p>
              <p id="p0035">Several window trials have used immunohistochemistry to investigate metformin's clinical effects in breast, endometrial, and prostate cancer. A number have shown that metformin can reduce the proliferation marker Ki67, but no singular mechanism has been clearly demonstrated. Activation of AMPK suggestive of an energy stress has been observed, while other studies have demonstrated reduced pAKT consistent with decreased insulin signaling (<xref rid="bib13" ref-type="bibr">Dowling et al., 2015</xref>, <xref rid="bib20" ref-type="bibr">Hadad et al., 2011</xref>, <xref rid="bib35" ref-type="bibr">Schuler et al., 2015</xref>). Recently published work by Liu et al. comparing the metabolite profile of ten ovarian tumor samples from patients on metformin versus ten control samples (patients not on metformin) demonstrated decreases in the levels of some TCA cycle intermediates and short-chain acyl-carnitines. In addition, the response to metformin seen in the human metabolite profiles could be recapitulated in a mouse model and <italic>in vitro</italic> when nutrient concentrations were limited (<xref rid="bib26" ref-type="bibr">Liu et al., 2016</xref>). To date, this is the most convincing clinical evidence that metformin has significant and measurable mitochondrial effects at standard therapeutic doses. Here, we present the results of a clinical study that integrates tumor metabolomic profiling with dynamic imaging, transcriptomics, and systemic metabolic markers to further dissect the effects of metformin on systemic and breast tumor metabolism.</p>
              <p id="p0040">We recruited 40 female patients with treatment-naive primary breast cancer to the study. Before and after a 13- to 21-day course of metformin, patients underwent a dynamic fluoro-deoxy-D-glucose positron emission tomography-computed tomography (FDG-PET-CT) scan, breast core biopsies from the primary tumor under ultrasound guidance, and blood samples to assay host metabolic markers of the insulin axis (<xref rid="fig1" ref-type="fig">Figure 1</xref>A). See <xref rid="mmc1" ref-type="supplementary-material">Table S1</xref> for details of study entry criteria and <xref rid="mmc1" ref-type="supplementary-material">Table S2</xref> for tumor features. See <xref rid="app2" ref-type="sec">Supplemental Information</xref> for further detail.<fig id="fig1"><label>Figure 1</label><caption><p>Trial Design and Imaging Analysis</p><p>(A) Study design. Shortly after diagnosis, patients with untreated primary breast cancer received 13–21 days of slow release metformin at escalating dose levels (500 mg for days 1<bold>–</bold>3, 1,000 mg for days 4–6, and 1,500 mg thereafter) with core biopsies taken pre- and post-metformin before proceeding to neoadjuvant chemotherapy.</p><p>(B) Change in the FDG flux constant K<sub>FDG-2cpt</sub> of the primary tumor in individual patients (left panel) and overall (lower right panel) pre- and post-metformin (n = 36, paired t test; data shown are means ± SEM). Upper right panel: static PET-CT images in coronal plane pre- and post-metformin are from an individual with an increase in K<sub>FDG-2cpt</sub> following metformin; note increased uptake in axillary lymph nodes (circled).</p><p>(C) Median fold change and interquartile range for metabolites pre- and post-metformin. Metabolites with statistically significant absolute change on Wilcoxon signed rank test are shown in red with p values (n = 29).</p><p>See also <xref rid="mmc1" ref-type="supplementary-material">Figure S1</xref> and <xref rid="mmc1" ref-type="supplementary-material">Tables S1–S3</xref>.</p></caption><graphic xlink:href="gr1"/></fig></p>
            </sec>
            <sec id="sec2">
              <title>Results and Discussion</title>
              <sec id="sec2.1">
                <title>Metformin Increases FDG Flux into Primary Breast Tumors</title>
                <p id="p0045">Pre-clinical data have shown that inhibition of oxidative phosphorylation (OXPHOS) by metformin increases dependence on glycolysis (<xref rid="bib2" ref-type="bibr">Ben Sahra et al., 2010</xref>, <xref rid="bib4" ref-type="bibr">Birsoy et al., 2014</xref>, <xref rid="bib38" ref-type="bibr">Wheaton et al., 2014</xref>). The FDG radio-tracer is a marker of tissue glucose utilization. Kinetics analysis of FDG uptake time courses obtained from dynamic PET images potentially provides more consistent measures of tumor tracer uptake, adjusted for variations in tracer inflow to the tumor, than standard static FDG-PET-CT (<xref rid="bib15" ref-type="bibr">Dunnwald et al., 2011</xref>). Using an irreversible two-tissue compartment model describing rates of FDG transport and phosphorylation (<xref rid="sec3" ref-type="sec">STAR Methods</xref>), we observed an increase in FDG flux (K<sub>FDG</sub>) into the primary breast cancer following metformin (<xref rid="fig1" ref-type="fig">Figure 1</xref>B) but no change in the static uptake measures SUL<sub>max</sub> and SUL<sub>mean</sub> for tumor (standardized uptake values normalized for lean body mass) (<xref rid="mmc1" ref-type="supplementary-material">Figures S1</xref>A and S1B; <xref rid="mmc1" ref-type="supplementary-material">Table S3</xref>). There was no change in nodal SUL<sub>max</sub> for patients with FDG avidity within ipsilateral axillary lymph nodes (<xref rid="mmc1" ref-type="supplementary-material">Figure S1</xref>C). There was a significant correlation between change in K<sub>FDG</sub> in the primary tumor and change in SUL<sub>max</sub> in the axillary nodes (<xref rid="mmc1" ref-type="supplementary-material">Figure S1</xref>D).</p>
                <p id="p0050">The above findings infer that metformin treatment leads to increased glucose uptake by breast tumors and this would be consistent with a switch to glycolytic metabolism. In addition, the analysis emphasizes the sensitivity of dynamic FDG-PET over static scanning in identifying subtle pharmacodynamic changes in glucose metabolism. If normal tissues such as liver absorbed more FDG in response to metformin, FDG activity concentrations in the blood would fall, potentially reducing FDG uptake by the tumor. However, the compartment model/flux constant approach describes tumor FDG uptake after allowing for differences across the whole time course of the dynamic scan in levels of blood-borne tracer flowing into the tumor, determined from imaged activity concentrations in the descending aorta. It is possible that it is precisely because this model controls for the flow of tracer into the tumor that we see a significant change in the flux constant and not standardized uptake values on static PET scanning.</p>
              </sec>
              <sec id="sec2.2">
                <title>Two Tumor Groups with Distinct Metabolic Responses to Metformin</title>
                <p id="p0055">We did not observe changes in the levels of the TCA cycle intermediates citrate, succinate, fumarate, and malate in contrast to <xref rid="bib26" ref-type="bibr">Liu et al. (2016)</xref>, or aspartate, a key marker of electron transport chain integrity (<xref rid="fig1" ref-type="fig">Figure 1</xref>C). Ornithine is condensed with carbamoyl phosphate to produce citrulline in the only intra-mitochondrial reaction of the urea cycle and citrulline levels decreased (mean log2FC = −0.53; p = 0.007). Some investigators have observed an increase in the ADP/ATP and AMP/ATP ratios typically under <italic>in vitro</italic> nutrient-deprived conditions but there was no significant increase in intratumoral ADP/ATP or AMP/ATP ratios post-metformin (<xref rid="mmc1" ref-type="supplementary-material">Figure S1</xref>E), and this is consistent with metabolomic data from ovarian tumors published in <xref rid="bib26" ref-type="bibr">Liu et al. (2016)</xref>. The discordance in findings with metabolomic profiling from pre-clinical studies may reflect the heterogeneity inherent in a study analyzing clinical samples and the difficulty of making very precise measurements when there may be only small changes in the levels of these metabolites. Mitochondrial dysfunction under the tissue culture conditions described in the literature cited above is likely to be greater than in our study. Indeed, <xref rid="bib17" ref-type="bibr">Gaude et al. (2018)</xref> showed that, at lower levels of mitochondrial dysfunction, there was little or no decrease in TCA cycle metabolites and aspartate. Uptake from the stroma in an <italic>in vivo</italic> system may help maintain aspartate levels (for example, <xref rid="bib5" ref-type="bibr">Birsoy et al., 2015</xref> used a cell line lacking in the transporter SLC1A3, which was expressed at the mRNA level in our clinical samples). In contrast to findings in some other studies (<xref rid="bib13" ref-type="bibr">Dowling et al., 2015</xref>, <xref rid="bib20" ref-type="bibr">Hadad et al., 2011</xref>) tumor immunohistochemistry demonstrated no change in AMPK phosphorylation following metformin (paired t test, p = 0.801) (<xref rid="mmc1" ref-type="supplementary-material">Figure S1</xref>F). There was no correlation between change in pAMPK and change in K<sub>FDG</sub> (<xref rid="mmc1" ref-type="supplementary-material">Figure S1</xref>G).</p>
                <p id="p0060">Whole-transcriptome RNA sequencing pre- and post-metformin revealed significant upregulation of several pathways linked to metabolism (<xref rid="fig2" ref-type="fig">Figure 2</xref>A) and more specifically to mitochondrial pathways and disease (<xref rid="mmc1" ref-type="supplementary-material">Table S4</xref>). This included four KEGG pathways that we predicted would be targeted by metformin based on extensive pre-clinical data (<xref rid="bib4" ref-type="bibr">Birsoy et al., 2014</xref>, <xref rid="bib16" ref-type="bibr">Fendt et al., 2013</xref>, <xref rid="bib26" ref-type="bibr">Liu et al., 2016</xref>, <xref rid="bib30" ref-type="bibr">Mullen et al., 2011</xref>, <xref rid="bib38" ref-type="bibr">Wheaton et al., 2014</xref>): oxidative phosphorylation (KEGG:00190); TCA cycle (KEGG:00020); glycolysis and gluconeogenesis (KEGG:00010); and alanine, aspartate, and glutamate metabolism (KEGG:00250). Taking all genes that were significantly up- or downregulated from these pathways we observed that for one hierarchical cluster of patients fold change in expression was strikingly increased for this set of genes (OXPHOS responders or OTR [OXPHOS transcriptional response]). All patients in the OTR group were estrogen receptor-positive (<xref rid="fig2" ref-type="fig">Figure 2</xref>B). Coherent with this observation, unsupervised hierarchical clustering of the expressed nuclear whole transcriptome showed that patients in the OTR group also clustered together in this analysis (<xref rid="mmc1" ref-type="supplementary-material">Figure S2</xref>A). Notably, clustering of the OTR group also occurred for expressed genes of the mitochondrial transcriptome (<xref rid="mmc1" ref-type="supplementary-material">Figure S2</xref>B). For patients with limited OTR there was evidence of increased glucose uptake defined by an increase in K<sub>FDG</sub> (FDG responders or FR) in contrast to the OTR group.<fig id="fig2"><label>Figure 2</label><caption><p>Metformin Alters Levels of Mitochondrial Metabolites and Increases OXPHOS Relevant Gene Transcription in a Subset of Patients</p><p>(A and B) Circos plot to show all significantly upregulated metabolic pathways in the KEGG database. The width of the outer and inner circles show the mean relative abundances for the broadest hierarchy and secondary hierarchy. The bars in the innermost circle represent the mean relative abundances for genes encoding proteins within the individual pathways. The curved lines link genes that are shared among different pathways as indexed by KEGG (A). Heatmap of differentially expressed genes from the following KEGG pathways: oxidative phosphorylation (KEGG:00190); TCA cycle (KEGG:00020); glycolysis and gluconeogenesis (KEGG:00010); alanine, aspartate, and glutamate metabolism (KEGG:00250). Each row represents a gene and each column represents a single patient (n = 36). Colors reflect the fold change for each gene post-metformin: red, upregulation; blue, downregulation. Samples were visually clustered using hierarchical clustering. OXPHOS transcriptional response (OTR) and FDG response (FR) groups shown. Shown below is heatmap of change in significantly altered metabolites and K<sub>FDG-2cpt</sub> (all post minus pre) for same individual patients (B).</p><p>(C) Scatterplot to show for the OTR and FR groups change in K<sub>FDG-2cpt</sub> and acetylcarnitine levels for the breast primary tumor (both post minus pre). Data shown are means ± SEM, unpaired t test.</p><p>(D) Correlation between change in K<sub>FDG-2cpt</sub> and acetylcarnitine (both post minus pre). Spearman's rank correlation coefficient and significance are shown.</p><p>See also <xref rid="mmc1" ref-type="supplementary-material">Figure S2</xref> and <xref rid="mmc1" ref-type="supplementary-material">Table S4</xref>.</p></caption><graphic xlink:href="gr2"/></fig></p>
                <p id="p0065">Consistent with mitochondrial targeting it has recently been shown that metformin treatment leads to a decrease in the levels of short-chain acyl-carnitines in ovarian cancer (<xref rid="bib26" ref-type="bibr">Liu et al., 2016</xref>). Metabolomic profiling of paired pre- and post-metformin samples showed that acetyl- and propionylcarnitine levels decrease (mean log<sub>2</sub>FC = −1.32, p = 0.046 and log<sub>2</sub>FC = −1.01, p = 0.039, respectively). Acetylcarnitine is a short-chain acyl-carnitine derived from glucose carbons (<xref rid="bib34" ref-type="bibr">Schooneman et al., 2013</xref>) and, in contrast to the OTR group, their FR counterparts were able to maintain acetylcarnitine levels (<xref rid="fig2" ref-type="fig">Figure 2</xref>C). There was a strong correlation between change in K<sub>FDG</sub> and change in acetylcarnitine levels (<xref rid="fig2" ref-type="fig">Figure 2</xref>D). <xref rid="mmc1" ref-type="supplementary-material">Figure S2</xref>C shows the interquartile range and median fold change for metabolites in the OTR and FR groups. It is unclear why intratumoral acetylcarnitine levels dropped, and this finding is at odds with <xref rid="bib10" ref-type="bibr">Chen et al. (2016)</xref>, who showed that complex 1 inhibition in a cell line model resulted in a severalfold increase in acetylcarnitine levels within whole cells and mitochondria. However, this may be due to the discordance between the very different environmental conditions and strength of mitochondrial inhibition in our clinical study compared with cell line models. In addition, Chen et al. only assayed the mitochondrial matrix, and used a different complex 1 inhibitor in a non-breast cancer model. Notably, carnitine o-acetyltransferase, which catalyzes the bidirectional conversion of acetylcarnitine to acetyl-coenzyme A (CoA) within both mitochondria and peroxisomes, was differentially upregulated in the OTR group (all <xref rid="fig3" ref-type="fig">Figure 3</xref>A). Hence, we speculate that altered flux in this pathway may be a consequence of metformin treatment. The positive correlation between change in FDG flux and intratumoral acetylcarnitine levels possibly reflects increased flux of glucose carbons toward acetyl-CoA. To fully understand the effects of metformin and mitochondrial defects on acyl-carnitine metabolism will require further work in pre-clinical models.<fig id="fig3"><label>Figure 3</label><caption><p>Effect of Metformin on Systemic Metabolism</p><p>(A) Change in expression of genes involved in regulation of aspartate/malate shuttle and oxidative and reductive metabolism, unpaired t test (n = 36). Data shown are means ± SEM. <sup>∗</sup>p &lt; 0.05; <sup>∗∗</sup>p &lt; 0.01; <sup>∗∗∗</sup>p &lt; 0.001.</p><p>(B) Pre- and post-metformin serum glucose, insulin, insulin growth factor-1 levels, and HOMA score for individual patients. Significant decrease for each host metabolic marker, p value shown (paired t test, n = 40).</p><p>(C) Venn diagram to show overlap of all genes whose change in expression correlated with either change in systemic levels of circulating c-peptide or tumor K<sub>FDG-2cpt</sub> or tumor acetylcarnitine.</p><p>(D and E) Correlation between peak serum metformin levels (2 hr post dose) and tumor metformin levels (D). Correlation between change in K<sub>FDG-2cpt</sub> (post minus pre) and GLUT1 expression (log2FC) for the breast primary tumor (E). Spearman's rank correlation coefficient and significance are shown for (D) and (E).</p><p>See also <xref rid="mmc1" ref-type="supplementary-material">Figure S3</xref> and <xref rid="mmc1" ref-type="supplementary-material">Tables S5</xref> and <xref rid="mmc1" ref-type="supplementary-material">S6</xref>.</p></caption><graphic xlink:href="gr3"/></fig></p>
                <p id="p0070">Maintaining aspartate levels has been shown to be a key resistance mechanism to electron transport chain inhibition and biguanides (<xref rid="bib5" ref-type="bibr">Birsoy et al., 2015</xref>, <xref rid="bib7" ref-type="bibr">Cardaci et al., 2015</xref>, <xref rid="bib37" ref-type="bibr">Sullivan et al., 2015</xref>). There was no difference in aspartate metabolite levels between the FR and OTR groups (<xref rid="fig1" ref-type="fig">Figures 1</xref>C and <xref rid="mmc1" ref-type="supplementary-material">S3</xref>A). However, several genes involved in aspartate metabolism were significantly upregulated and it was striking that the increase in expression of three of the five genes that encode for units of the malate-aspartate shuttle (GOT2, MDH1, and MDH2) was significantly greater in the OTR group compared with the FR group (<xref rid="fig3" ref-type="fig">Figure 3</xref>A). Dependency on glutamine as a source of citrate for either lipid or aspartate biosynthesis has been shown to be a key resistance mechanism to metformin and other mitochondrial insults (<xref rid="bib5" ref-type="bibr">Birsoy et al., 2015</xref>, <xref rid="bib16" ref-type="bibr">Fendt et al., 2013</xref>, <xref rid="bib30" ref-type="bibr">Mullen et al., 2011</xref>) and we observed increased expression of multiple genes that regulate glutamine metabolism. Two key checkpoints in this process were differentially upregulated in the OTR group, mitochondrial isocitrate dehydrogenase (IDH2) and the citrate transporter, SLC25A1, which delivers glutamine-derived citrate to the cytosol where it is cleaved by ATP citrate lyase to oxaloacetate and acetyl-CoA for aspartate and lipid synthesis, respectively (<xref rid="fig3" ref-type="fig">Figure 3</xref>A). Previous work has also shown that both isoforms of isocitrate dehydrogenase, IDH1 and IDH2, support growth in cells that use glutamine-dependent reductive carboxylation. Hence, tumors harboring IDH mutations may be more susceptible to biguanide therapy.</p>
              </sec>
              <sec id="sec2.3">
                <title>Systemic Response to Metformin Does Not Correlate with Change in Intratumoral Assays</title>
                <p id="p0075">Metformin has been shown to modulate a number of systemic metabolic and inflammatory markers in diabetic populations. In our study metformin lowered circulating levels of serum glucose, insulin, c-peptide, and an insulin resistance score (homeostatic model assessment or HOMA), but not leptin, adiponectin, C-reactive protein, tumor necrosis factor α, or interleukin-6 (<xref rid="fig3" ref-type="fig">Figures 3</xref>B and <xref rid="mmc1" ref-type="supplementary-material">S3</xref>B; <xref rid="mmc1" ref-type="supplementary-material">Table S5</xref>). However, there were no significant differences between the OTR and FR groups in pre-/post-metformin changes in levels of any of these circulating metabolic markers (<xref rid="mmc1" ref-type="supplementary-material">Figure S3</xref>C). There was a marked overlap in genes whose change in expression correlated with change in K<sub>FDG</sub> and change in acetylcarnitine (hypergeometric test, p &lt; 0.00001), but little corresponding overlap with genes related to change in c-peptide, glucose, insulin, or HOMA (<xref rid="fig3" ref-type="fig">Figures 3</xref>C and <xref rid="mmc1" ref-type="supplementary-material">S3</xref>D). Eighteen of the genes correlating with change in K<sub>FDG</sub> and acetylcarnitine were KEGG-annotated metabolism genes most notably associated with oxidative phosphorylation, carbohydrate, amino acid, and nucleotide metabolism pathways (<xref rid="mmc1" ref-type="supplementary-material">Table S6</xref>). There was an increase in pAKT expression on tumor immunohistochemistry (paired t test, p = 0.026), but no correlation between change in pAKT expression and change in c-peptide, glucose, insulin, or HOMA, and no significant difference between the FR and OTR groups (<xref rid="mmc1" ref-type="supplementary-material">Figures S3</xref>E–S3G). There was also no difference in pAMPK expression between the FR and OTR groups (<xref rid="mmc1" ref-type="supplementary-material">Figure S3</xref>G).</p>
                <p id="p0080">The increase in tumor pAKT expression was unexpected and not consistent with a decrease in insulin receptor signaling or findings in prior studies. AKT activation increases ATP levels in cells and has been identified in a number of studies as being a key player in the regulation of both glycolysis and oxidative phosphorylation (<xref rid="bib32" ref-type="bibr">Robey and Hay, 2009</xref>). Recent work has shown that mitochondrial AKT activation occurs in the context of tumor energy and hypoxic stress, switching metabolism toward glycolysis (<xref rid="bib8" ref-type="bibr">Chae et al., 2016</xref>). However, we cannot exclude metformin's systemic effects on host metabolism being a significant factor in modulating tumor metabolism and proliferation, and indeed we would expect a decrease in insulin levels to have some effect on tumor intracellular signaling. Our study only recruited patients with normal systemic glucose levels, and for patients with diabetes or glucose intolerance any effect on insulin signaling via the hypoglycemic activity of metformin is likely to be greater.</p>
                <p id="p0085">We then investigated the relationship between tumor metformin levels and metabolic response. Although serum and tumor levels were significantly correlated with each other (<xref rid="fig3" ref-type="fig">Figure 3</xref>D) they did not differ between the OTR and FR groups (<xref rid="mmc1" ref-type="supplementary-material">Figure S4</xref>A). Previously published pre-clinical data suggested that expression of the organic cation transporter, OCT1 (encoded by gene SLC22A1), is required for tumor uptake of metformin and metabolic response (<xref rid="bib9" ref-type="bibr">Chandel et al., 2016</xref>, <xref rid="bib12" ref-type="bibr">Dowling et al., 2016</xref>). There was no significant correlation between baseline OCT1 gene expression and tumor metformin levels but notably the patient with highest tumor metformin levels also had the greatest expression of tumor OCT1 (<xref rid="mmc1" ref-type="supplementary-material">Figure S4</xref>B). Furthermore, there was no difference in baseline OCT1 expression between the OTR and FR groups (<xref rid="mmc1" ref-type="supplementary-material">Figure S4</xref>C). Baseline OCT1 expression did correlate with change in K<sub>FDG</sub>, although the relevance of this finding is unclear given that there was no such relationship with tumor metformin levels (<xref rid="mmc1" ref-type="supplementary-material">Figure S4</xref>D).</p>
                <p id="p0090">Glucose transporter gene expression may determine the sensitivity of cell lines to biguanides (<xref rid="bib4" ref-type="bibr">Birsoy et al., 2014</xref>). Expression of the glucose transporter, GLUT1 (encoded by gene SLC2A1), has previously been shown to correlate with uptake of FDG on PET-CT (<xref rid="bib6" ref-type="bibr">Bos et al., 2002</xref>), and in our study change in K<sub>FDG</sub> positively correlated with the change in expression of GLUT1 (<xref rid="fig3" ref-type="fig">Figure 3</xref>E). However, there was no significant difference in GLUT1 expression between the two groups although there was for another glucose transporter, GLUT4 (encoded by gene SLC2A4) (<xref rid="mmc1" ref-type="supplementary-material">Figure S4</xref>E).</p>
              </sec>
              <sec id="sec2.4">
                <title>OTR to Metformin Relates to Change in a Proliferation Metagene</title>
                <p id="p0095">Several clinical studies have shown that metformin can reduce breast, prostate, and endometrial cancer cell proliferation (<xref rid="bib20" ref-type="bibr">Hadad et al., 2011</xref>, <xref rid="bib23" ref-type="bibr">Joshua et al., 2014</xref>, <xref rid="bib24" ref-type="bibr">Laskov et al., 2014</xref>, <xref rid="bib29" ref-type="bibr">Mitsuhashi et al., 2014</xref>, <xref rid="bib31" ref-type="bibr">Niraula et al., 2012</xref>, <xref rid="bib35" ref-type="bibr">Schuler et al., 2015</xref>). We explored the effect of metformin on a validated human breast cancer proliferation signature (<xref rid="bib11" ref-type="bibr">Desmedt et al., 2008</xref>) and overall observed no significant change following metformin treatment (<xref rid="fig4" ref-type="fig">Figure 4</xref>). However, it was striking that an increase in metagene expression occurred in the OTR group, while, in contrast, there was a decrease for several patients in the FR group, the change in metagene expression consequently differing significantly between the two groups (<xref rid="fig4" ref-type="fig">Figure 4</xref>). Under <italic>in vitro</italic> low-glucose conditions the ability for cell lines to upregulate OXPHOS predicts for sensitivity to biguanides (<xref rid="bib4" ref-type="bibr">Birsoy et al., 2014</xref>), and our data suggest that a reactive increase in OXPHOS and aspartate synthesis gene transcription may be critical for resistance to metformin. None of the circulating or tumor immunohistochemical markers, metformin levels, K<sub>FDG</sub>, or significantly altered metabolites correlated with change in expression of the proliferation metagene (<xref rid="mmc1" ref-type="supplementary-material">Figure S4</xref>F).<fig id="fig4"><label>Figure 4</label><caption><p>Effect of Metformin on Proliferation</p><p>Left panel: heatmap of genes from the proliferation signature. Each row represents a gene and each column represents a single patient. Colors reflect the fold change for each gene post-metformin: red, upregulation; blue, downregulation. Samples were visually clustered using hierarchical clustering. Right upper panel: pre- and post-metformin expression of signatures for individual patients (n = 36); right lower panel, scatterplot to show change in expression of signatures for the OTR and FR groups. Data shown are means ± SEM, unpaired t test (n = 36).</p></caption><graphic xlink:href="gr4"/></fig></p>
              </sec>
              <sec id="sec2.5">
                <title>Conclusion and Perspectives</title>
                <p id="p0100">Our work outlines two types of breast cancer metabolic response to metformin and links the effects of metformin on mitochondrial metabolism with its effects on breast cancer proliferation at a transcriptional level. Tumors that were able to upregulate OXPHOS gene transcription in response to metformin showed an increase in their proliferation score suggestive of resistance following metformin treatment.</p>
                <p id="p0105">The upregulation of multiple transcriptomic pathways involved in mitochondrial metabolism and decrease in levels of several intratumoral mitochondrial metabolites is suggestive of metformin interfering with mitochondrial metabolism. Furthermore, the increased expression of multiple genes regulating glycolysis and glucose transport alongside our imaging data is consistent with mobilization of glucose metabolism in response to metformin. The upregulation of key regulatory genes for glycolysis, aspartate, and glutamine metabolism in response to metformin may represent a mechanism of resistance and confirms the potential of previously proposed strategies to target these pathways, for example, by combining biguanides with glutaminase inhibitors or dichloroacetate (<xref rid="bib16" ref-type="bibr">Fendt et al., 2013</xref>, <xref rid="bib21" ref-type="bibr">Haugrud et al., 2014</xref>). Estrogen receptor expression may also act as a biomarker to distinguish the two types of metabolic response. Among the most likely determinants for resistance in our view are mitochondrial defects (for example, mutations in complex 1 genes), and this would be consistent with <italic>in vitro</italic> data (<xref rid="bib4" ref-type="bibr">Birsoy et al., 2014</xref>). Hence, we propose that translational work within ongoing phase 3 trials should investigate whether mitochondrial mutations herald biguanide sensitivity and clinical outcome. However, we emphasize that early dynamic monitoring of response may detect the heterogeneity that cannot be detectable at baseline.</p>
                <p id="p0110">There have been a number of other window studies designed to assess metformin's pharmacodynamic effects in several different tumor types and it is important to note the differences to this study. Most of these trials have used immunohistochemical approaches on a wide range of markers, but in particular Ki67, AMPK, and markers of apoptosis with discrepant results (<xref rid="bib13" ref-type="bibr">Dowling et al., 2015</xref>, <xref rid="bib20" ref-type="bibr">Hadad et al., 2011</xref>, <xref rid="bib35" ref-type="bibr">Schuler et al., 2015</xref>). The most in-depth clinical study to date to use metabolomic approaches, <xref rid="bib26" ref-type="bibr">Liu et al. (2016)</xref>, suggested some evidence of mitochondrial interference but, in contrast to our study, did not take serial biopsies to allow identification of differential types of response and was limited to effectively one assay. In addition, Liu et al. assayed samples taken from ten patients with ovarian cancer who happened to be receiving metformin for diabetes while using control samples from non-diabetic patients with a lower mean body mass index. Hence, this was a comparison between two patient groups with distinct host metabolism (<xref rid="bib26" ref-type="bibr">Liu et al., 2016</xref>). In contrast, this study only recruited from a non-diabetic population, the focus of ongoing phase 3 trials.</p>
                <p id="p0115">These data are consistent with several of the observations seen previously using <italic>in vitro</italic> and <italic>in vivo</italic> models but it is still uncertain whether these perturbations are enough for metformin to deliver clinical benefit to patients. A recent substudy of the ALTTO phase 3 adjuvant breast cancer trial reported a strong association between metformin and improved overall survival in diabetic patients (<xref rid="bib36" ref-type="bibr">Sonnenblick et al., 2017</xref>). Our observations make the case for the continued clinical study of metformin and more potent biguanides (<xref rid="bib39" ref-type="bibr">Zhang et al., 2016</xref>) in non-diabetic patients. The results of ongoing phase 3 trials are awaited (<xref rid="bib18" ref-type="bibr">Gillessen et al., 2016</xref>, <xref rid="bib19" ref-type="bibr">Goodwin et al., 2015</xref>).</p>
              </sec>
              <sec id="sec2.6">
                <title>Limitations of Study</title>
                <p id="p0120">This study had no control arm and hence it is possible that some of the observations could be related to the passage of time or interventions (e.g., biopsies). Given the nature of this clinical translational study the analysis especially relies on correlative evaluation and hence we cannot rule out a link between the systemic effects of metformin and significant changes in tumor metabolism and proliferation. Although 40 patients are a substantial number for an involved pharmacodynamic study of this type, correlations across the assays were not able to be carried out across the full cohort for varied reasons (technical difficulties with some scans and insufficient sample to carry out all assays, etc.) and increased recruitment would provide greater power for the analyses.</p>
              </sec>
            </sec>
            <sec id="sec3">
              <title>STAR★Methods</title>
              <sec id="sec3.1">
                <title>Key Resources Table</title>
                <p id="p0125">
                  <table-wrap id="undtbl1" position="float">
                    <table frame="hsides" rules="groups">
                      <thead>
                        <tr>
                          <th>REAGENT or RESOURCE</th>
                          <th>SOURCE</th>
                          <th>IDENTIFIER</th>
                        </tr>
                      </thead>
                      <tbody>
                        <tr>
                          <td colspan="3">
                            <bold>Antibodies</bold>
                          </td>
                        </tr>
                        <tr>
                          <td colspan="3">
                            <hr/>
                          </td>
                        </tr>
                        <tr>
                          <td>pAMPK thr172 residue</td>
                          <td>Cell Signaling Technologies</td>
                          <td>RRID: <ext-link ext-link-type="uri" xlink:href="nif-antibody:AB_331250" id="intref0010">AB_331250</ext-link></td>
                        </tr>
                        <tr>
                          <td>pAKT ser473 residue</td>
                          <td>Cell Signaling Technologies</td>
                          <td>RRID: <ext-link ext-link-type="uri" xlink:href="nif-antibody:AB_2315049" id="intref0015">AB_2315049</ext-link></td>
                        </tr>
                        <tr>
                          <td colspan="3">
                            <hr/>
                          </td>
                        </tr>
                        <tr>
                          <td colspan="3">
                            <bold>Critical Commercial Assays</bold>
                          </td>
                        </tr>
                        <tr>
                          <td colspan="3">
                            <hr/>
                          </td>
                        </tr>
                        <tr>
                          <td>IL-6</td>
                          <td>Invitrogen</td>
                          <td>BMS213HS</td>
                        </tr>
                        <tr>
                          <td>TNF-alpha</td>
                          <td>Invitrogen</td>
                          <td>BMS223HS</td>
                        </tr>
                        <tr>
                          <td>NEBNext mRNA Library Prep Master Mix Set</td>
                          <td>New England Biolabs</td>
                          <td>E6110</td>
                        </tr>
                        <tr>
                          <td colspan="3">
                            <hr/>
                          </td>
                        </tr>
                        <tr>
                          <td colspan="3">
                            <bold>Deposited Data</bold>
                          </td>
                        </tr>
                        <tr>
                          <td colspan="3">
                            <hr/>
                          </td>
                        </tr>
                        <tr>
                          <td>Analysed RNASeq data</td>
                          <td>This paper</td>
                          <td>
                            <ext-link ext-link-type="uri" xlink:href="http://dx.doi.org/10.17632/cytrpb62f2.1" id="interref0015">http://dx.doi.org/10.17632/cytrpb62f2.1</ext-link>
                          </td>
                        </tr>
                        <tr>
                          <td colspan="3">
                            <hr/>
                          </td>
                        </tr>
                        <tr>
                          <td colspan="3">
                            <bold>Software and Algorithms</bold>
                          </td>
                        </tr>
                        <tr>
                          <td colspan="3">
                            <hr/>
                          </td>
                        </tr>
                        <tr>
                          <td>RNASeq analysis</td>
                          <td>R-project</td>
                          <td>v3.3.1</td>
                        </tr>
                        <tr>
                          <td>Imaging analysis</td>
                          <td>Matlab</td>
                          <td>N/A</td>
                        </tr>
                        <tr>
                          <td>Other statistical analyses</td>
                          <td>GraphPad PRISM</td>
                          <td>v6.0</td>
                        </tr>
                        <tr>
                          <td colspan="3">
                            <hr/>
                          </td>
                        </tr>
                        <tr>
                          <td colspan="3">
                            <bold>Other</bold>
                          </td>
                        </tr>
                        <tr>
                          <td colspan="3">
                            <hr/>
                          </td>
                        </tr>
                        <tr>
                          <td>Metformin</td>
                          <td>Bristol-Myers Squibb</td>
                          <td>Glucophage XR</td>
                        </tr>
                        <tr>
                          <td>ClinicalTrials.gov Identifier</td>
                          <td>N/A</td>
                          <td>
                            <ext-link ext-link-type="ClinicalTrials.gov" xlink:href="NCT01266486" id="intref0025">NCT01266486</ext-link>
                          </td>
                        </tr>
                      </tbody>
                    </table>
                  </table-wrap>
                </p>
              </sec>
              <sec id="sec3.2">
                <title>Contact for Reagent and Resource Sharing</title>
                <p id="p0130">Further information and requests for resources should be directed to and will be fulfilled by the Lead Contact, Simon Lord (<ext-link ext-link-type="uri" xlink:href="mailto:simon.lord@oncology.ox.ac.uk" id="intref0030">simon.lord@oncology.ox.ac.uk</ext-link>).</p>
              </sec>
              <sec id="sec3.3">
                <title>Method Details</title>
                <sec id="sec3.3.1">
                  <title>Clinical Study Design and Patient Selection</title>
                  <p id="p0135">Patients were recruited from the medical oncology breast cancer clinic over a period of 30 months between May 2011 and November 2013 in three UK centres, Oxford, Luton and Dundee. Informed consent was obtained from all patients. The study was prospectively approved by the NHS Oxfordshire Research Ethics Committee A and registered with the ClinicalTrials.gov identifier: <ext-link ext-link-type="ClinicalTrials.gov" xlink:href="NCT01266486" id="intref0035">NCT01266486</ext-link>. All patients at the point of recruitment had been referred with a view to neoadjuvant chemotherapy, had histologically confirmed breast cancer and gave informed consent. In all cases the primary breast cancer was <italic>in situ</italic> and no patients had received any prior treatment for breast cancer. See <xref rid="mmc1" ref-type="supplementary-material">Table S1</xref> for a list of key eligibility criteria. In total 41 patients were recruited and had evaluable data. See <xref rid="mmc1" ref-type="supplementary-material">Table S2</xref> for numbers of patients with sufficient data for paired analysis for each assay. All patients were female and the median age at study entry was 49 years (range 27 – 67 years). Median body mass index at study entry was 28.1 (range 19.6 – 45.3).</p>
                  <p id="p0140">Metformin was given in the Glucophage XR formulation in an escalating dose once daily for a minimum of 13 days and a maximum of 21 days (500mg for days 1<bold>–</bold>3, 1000mg for days 4<bold>–</bold>6 and 1500mg thereafter). The day prior to commencing metformin a core biopsy was taken under ultrasound guidance from the periphery of the primary tumour. Within 1 minute of this procedure the biopsy material was snap frozen in liquid nitrogen prior to storage at -80°C. Prior to metabolomics analysis biopsy samples were divided and one portion used for broad metabolomics analysis and the other to generate a lipid profile.</p>
                </sec>
                <sec id="sec3.3.2">
                  <title>PET-CT Protocol</title>
                  <p id="p0145">The radiotracer, 2-deoxy-2-(18F)fluoro-D-glucose (<sup>18</sup>[F]-FDG), was used for all examinations. Prior to scanning, patients were fasted overnight for at least 8 hours but could drink water. Patients’ blood glucose was checked just prior to the scan with a portable blood glucose monitor to ensure it was &lt;7mmol/L. All scans took place on either a 3D mode time of flight GE Discovery 690 64-slice PET-CT system (GE Healthcare, Milwaukee) or Siemens Biograph mCT-128 (Siemens Healthcare, Germany).</p>
                  <p id="p0150">A dynamic acquisition of the breast tumour (and any lymph nodes within the PET field of view) was initiated with the patient imaged supine. Patients were injected with <sup>18</sup>[F]-FDG (3 MBq/kg, up to a maximum of 400 MBq) 30 seconds into PET imaging, which continued for 45 minutes. The 45 minutes of data were then reconstructed as a sequence of images describing average activity concentrations during a series of time frames (1x30s, 12x5s, 6x10s, 5x30s, 10x60s, 6x300s).</p>
                  <p id="p0155">50 minutes after injection, a static PET scan was performed from skull base to mid-thigh, acquiring data for four minutes at each bed position. Thus the primary breast cancer was scanned at approximately 60 minutes post injection, in addition to the dynamic PET scanning from 0-45 minutes. Prior to each PET acquisition a CT scan was performed for localization and PET attenuation correction, using a pitch of 0.984, 120 kV, automA with a noise index of 25.</p>
                  <p id="p0160">The PET images were reconstructed on a matrix of 5.5×5.5×3.3 mm<sup>3</sup> voxels using filtered back projection for the dynamic sequence, and iterative reconstruction for the static scan. See <xref rid="app2" ref-type="sec">Supplemental Information</xref> for further details of static and kinetic analysis of imaging.</p>
                </sec>
                <sec id="sec3.3.3">
                  <title>Static PET-CT Analysis</title>
                  <p id="p0165">Tumour volumes were delineated on the 60-minute static FDG-PET scans by a nuclear medicine radiologist working on a Hermes workstation and using Hybrid viewer software (Hermes Medical Solutions AB, Stockholm, Sweden). Maximum and mean standardized uptake values (SUV) within each tumour volume were normalized by lean body mass (LBM) and reported as SUL<sub>mean</sub>=SUV<sub>mean</sub><sup>∗</sup>LBM/BW and SUL<sub>max</sub>=SUV<sub>max</sub><sup>∗</sup>LBM/BW respectively, where<disp-formula id="ufd1"><mml:math id="M1" altimg="si1.gif" overflow="scroll"><mml:mrow><mml:msub><mml:mrow><mml:mtext>LBM</mml:mtext></mml:mrow><mml:mrow><mml:mtext>Hume</mml:mtext></mml:mrow></mml:msub><mml:mo>=</mml:mo><mml:mrow><mml:mo>{</mml:mo><mml:mrow><mml:mtable><mml:mtr><mml:mtd><mml:mrow><mml:mtext>0</mml:mtext><mml:mtext>.</mml:mtext><mml:mn>32810</mml:mn><mml:mspace width="0.25em"/><mml:mtext>×</mml:mtext><mml:mspace width="0.25em"/><mml:mtext>BW</mml:mtext><mml:mspace width="0.25em"/><mml:mo>+</mml:mo><mml:mspace width="0.25em"/><mml:mtext>0</mml:mtext><mml:mtext>.</mml:mtext><mml:mn>33929</mml:mn><mml:mspace width="0.25em"/><mml:mtext>×</mml:mtext><mml:mspace width="0.25em"/><mml:mtext>H</mml:mtext><mml:mspace width="0.25em"/><mml:mspace width="0.25em"/><mml:mtext>×</mml:mtext><mml:mspace width="0.25em"/><mml:mn>29</mml:mn><mml:mtext>.</mml:mtext><mml:mn>5336</mml:mn><mml:mspace width="0.25em"/><mml:mrow><mml:mo>(</mml:mo><mml:mrow><mml:mtext>Males</mml:mtext></mml:mrow><mml:mo>)</mml:mo></mml:mrow></mml:mrow></mml:mtd></mml:mtr><mml:mtr><mml:mtd><mml:mrow><mml:mtext>0</mml:mtext><mml:mtext>.</mml:mtext><mml:mn>29569</mml:mn><mml:mspace width="0.25em"/><mml:mtext>×</mml:mtext><mml:mspace width="0.25em"/><mml:mtext>BW</mml:mtext><mml:mspace width="0.25em"/><mml:mo>+</mml:mo><mml:mspace width="0.25em"/><mml:mtext>0</mml:mtext><mml:mtext>.</mml:mtext><mml:mn>41813</mml:mn><mml:mspace width="0.25em"/><mml:mtext>×</mml:mtext><mml:mspace width="0.25em"/><mml:mtext>H×</mml:mtext><mml:mspace width="0.25em"/><mml:mn>43</mml:mn><mml:mtext>.</mml:mtext><mml:mn>2933</mml:mn><mml:mspace width="0.25em"/><mml:mrow><mml:mo>(</mml:mo><mml:mrow><mml:mtext>Females</mml:mtext></mml:mrow><mml:mo>)</mml:mo></mml:mrow></mml:mrow></mml:mtd></mml:mtr></mml:mtable></mml:mrow></mml:mrow></mml:mrow></mml:math></disp-formula></p>
                  <p id="p0170">and BW and H are the body weight in kg and height in cm (<xref rid="bib22" ref-type="bibr">Hume, 1966</xref>).</p>
                </sec>
                <sec id="sec3.3.4">
                  <title>Dynamic PET-CT Analysis</title>
                  <p id="p0175">The tumour volume contoured on a static PET-CT image was transferred to the corresponding 0-45 minute dynamic FDG-PET scan by co-registering the two image sets. Time-activity curves (TACs) describing time-courses of mean tumour FDG activity concentration within the tumour were then calculated for the tumour regions of the dynamic scans. Time-courses of blood-borne tracer concentrations were similarly obtained from regions defined in the descending aorta (average 42 ± 4 slices with mean volume of 32 ± 11 cm<sup>3</sup>), and used to describe tracer inflow into tumours (‘input functions’, IF).</p>
                  <p id="p0180">Kinetic analysis of tumour FDG uptake was carried out for 36/40 patients, using irreversible 2- and 3-tissue compartment models (<xref rid="bib3" ref-type="bibr">Bertoldo et al., 2001</xref>). Tumour TACS for the remaining four patients were not analysed as they showed pronounced discontinuities, likely due to movement during scanning. The compartment models characterize FDG transport and intracellular phosphorylation using a small number of parameters, and enable modelled tumour TACs to be calculated directly from IFs. The models were fitted by adjusting the parameters to achieve the best weighted least-squares match between modelled and measured tumour TACs (<xref rid="bib25" ref-type="bibr">Liu et al., 2014</xref>).</p>
                  <p id="p0185">The 2-tissue compartment model (2cpt) provided better descriptions of tumour TAC data, judged by the Akaike and Bayesian information criteria (AIC and BIC) used alongside a runs-test. From each fit, estimated values and associated statistical uncertainties were obtained for the model parameters v<sub>B</sub>, K<sub>1</sub>, k<sub>2</sub> and k<sub>3</sub>, which respectively describe the fractional tumour blood volume and rate-constants for FDG transport back and forth between the vasculature and tumour cells, and for intra-cellular phosphorylation. Uncertainties on these fitted parameters are quite large due to statistical noise in dynamic PET images. Flux constants K<sub>FDG</sub>, numerically equal to K<sub>1</sub>k<sub>2</sub>/(k<sub>2</sub>+k<sub>3</sub>), were also calculated. Conceptually K<sub>FDG</sub> describes the rate of intra-cellular FDG phosphorylation when a steady-state unit concentration of FDG exists in the blood, and statistically it is estimated substantially more precisely than the individual model rate-constants. <xref rid="mmc1" ref-type="supplementary-material">Figure S5</xref> summarizes the analysis. Significances of differences in model parameters before and after metformin were assessed using paired t-test and Wilcoxon signed rank test. Only changes in K<sub>FDG</sub> proved significant.</p>
                  <p id="p0190">It was not useful to kinetically analyse FDG uptake time-courses in the axillary nodes, since the small nodal volumes led to a high degree of noise on the time-courses and fitted kinetics parameters including the flux constant. All patients included in the axillary node analysis who had lymph node avidity had evidence at pre-treatment biopsy or surgery of metastatic breast carcinoma involvement within the axillary nodes with the exception of 3 patients for whom no biopsy or surgical data was available.</p>
                </sec>
                <sec id="sec3.3.5">
                  <title>Mass Spectrometry Analysis of Clinical Samples for Metabolomic Profile</title>
                  <p id="p0195">Breast cancer tissue was pulverised via mechanical disruption (IKA Ultra-Turrax T-8 homogenizor) prior to hydrophilic extraction of intracellular metabolites from tissue using a methanol/acetonitrile/water (50/30/20) extraction solution (250 μL of extraction solution per 10mg homogenised tissue). Following thorough mixing, the samples were centrifuged for 10 minutes at 10,000G and the supernatant stored at -80°C prior to mass spectrometry analysis.</p>
                  <p id="p0200">For the LC separation, column A the sequant Zic-pHilic (150 mm × 2.1 mm i.d. 5 μm) with the guard column (20 mm × 2.1 mm i.d. 5 μm) from HiChrom, Reading, UK. Mobile phase A: 20 mM ammonium carbonate plus 0.1% ammonia hydroxide in water. Mobile phase B: acetonitrile. The flow rate was kept at 180 μL/minute and gradient as follow: 0–1 minutes 70% of B, 16 minutes 38% of B, 16.5 minutes 70% of B, 25 minutes 70% of B. The mass spectrometer (Thermo Q-Exactive Orbitrap) was operated in a polarity switching mode. Experimenters analysing samples from metabolomics experiments were blinded to the experimental interventions. Samples were randomised in order to avoid machine drifts.</p>
                </sec>
                <sec id="sec3.3.6">
                  <title>Analysis of RNASeq Data</title>
                  <p id="p0205">Next generation sequencing of ‘Poly (A) targeted’ mRNA, including library preparation, was carried out by the Oxford Genomics Centre core facility at the Welcome Trust Centre for Human Genetics. The NEBNext mRNA Library Prep Master Mix Set (New England Biolabs) was used for preparation of the expression libraries and the Illumina HiSeq 2000 system used to carry out the sequencing.</p>
                  <p id="p0210">Paired-read were aligned to human reference genome GRCh38, including transcriptomic information, by Bowtie 2.2.6 and Tophat v2.1. The fold change of normalized expression level, FPKM (Fragments Per Kilobase of transcript per Million mapped reads), for each gene was then estimated from those aligned reads using Cuffdiff 2.2.1. Non-parametric rank product (R package and version) was used to discover the genes with consistent statistically significant fold change (probability of false positive &lt; 0.05) between pre- and post-metformin treatment, among all patients were selected. This approach was preferred with respect to EdgeR (<xref rid="bib1" ref-type="bibr">Anders and Huber, 2010</xref>) and Deseq (<xref rid="bib27" ref-type="bibr">McCarthy et al., 2012</xref>, <xref rid="bib33" ref-type="bibr">Robinson et al., 2010</xref>) as in datasets with high variability and paired samples (pre and post- treatment) non parametric methods tend to work better in our previous studies (<xref rid="bib28" ref-type="bibr">Mehta et al., 2016</xref>); however analysis with EdgeR (version 3.16.5) and Deseq (version 1.26.0) was also done and did not change the main conclusions.</p>
                </sec>
                <sec id="sec3.3.7">
                  <title>Measurement of Circulating Markers</title>
                  <p id="p0215">Patient serum samples were collected after fasting overnight just prior to the breast core biopsy (and for the post-metformin sample 2 hours post-dose). Fasting glucose, insulin, c-peptide, c-reactive protein, leptin and adiponectin were measured using NHS biochemistry services to standardised and validated protocols. The homeostasis model assessment (HOMA) was calculated using the following equation: (glucose mmol/L <sup>∗</sup> insulin mU/L)/22.5.</p>
                  <p id="p0220">IL-6 and TNF-alpha were measured in duplicate by High Sensitivity enzyme linked immunosorbent assay (ELISA) (Invitrogen). These assays utilise two amplification steps, allowing for the detection of low levels of cytokines present in serum and plasma samples.</p>
                </sec>
                <sec id="sec3.3.8">
                  <title>Immunohistochemistry</title>
                  <p id="p0225">Staining for p-AMPK (1 in 200, thr172 residue, Cell Signaling Technologies #2535) and pAKT (1 in 100, ser473 residue, Cell Signaling Technologies #4060), was performed on a Leica Bond-max autostainer in the GCP laboratory, Department of Pharmacology, University of Oxford. For pAMPK, cell pellet controls were generated using MCF7 cells treated with either 20 μM Compound C (negative control) or 250 μM AICAR (positive control) for 24 hours prior to harvesting. For pAKT, cell pellet controls were generated using serum starved MCF7 cells either untreated (negative control) or treated with IGF-1 (positive control) for 30 minutes prior to harvesting and the generation of a formalin fixed, paraffin embedded cell pellet block.</p>
                  <p id="p0230">Quantitative scoring of the staining of complete tumour sections was evaluated by two accredited pathologists using high power fields the intensity of the immunostaining was classified into 4 categories: 0, no immunostaining present; 1, weak staining; 2, moderate staining; and 3, strong staining and the percentage of positive cells at each intensity was then classified into 4 groups; 1 (0-10% positive cells), 2 (11% to 50% positive cells), 3 (51% to 80% positive cells) or 4 (81 to 100% positive cells). The H-score of immunoreactivity was obtained by multiplying the intensity and percentage scores.</p>
                </sec>
              </sec>
              <sec id="sec3.4">
                <title>Quantification and Statistical Analysis</title>
                <p id="p0235">Processing for dynamic PET-CT and gene expression profiling are reported above. Absolute difference in metabolites was analysed using paired non-parametric method (Wilcoxon Signed Rank Sum). All other differences in measurements pre- and post-metformin were compared using paired t-tests. Correlation analyses between gene expression scores, metabolites, metformin levels, circulating metabolic markers and K<sub>FDG</sub> were performed using non-parametric methods (Spearman’s rank correlation coefficient). Differences in measurements between the OTR and FR groups were examined using an unpaired two-tailed t-test. Statistical tests for each analysis are defined in figure legends. In all cases a p-value &lt;0.05 was considered significant. Analysis of RNASeq and Metabolomic data was carried out using non-parametric approaches and hence the data was not required to follow an underlying distribution. Kinetic model fits to the tumour TACs extracted from dynamic PET scans were runs-tested as a non-parametric check on fit quality. Significances of pre/post metformin differences in PET tracer kinetics parameters and normalised static uptake values were assessed using a parametric t-test and a non-parametric Wilcoxon signed rank test, the assumption of normally-distributed data underlying the t-test being rejectable with p&lt;.05 for all variables except K1 according to the Shapiro-Wilk test. Statistical packages, GraphPad PRISM v6.0, R v3.3.1 and Matlab were used for analyses.</p>
                <sec id="sec3.4.1">
                  <title>Sample Size Estimation</title>
                  <p id="p0240">Based on our and others’ previous analyses of microarray data, a minimum of 20 cases with paired measurements at two time points were estimated to be sufficient to observe expression changes of at least 1.7-fold in genes showing a coefficient of variation at each time point up to 50% with a significance level after multiple test correction of p=0.05 (taking into account filtering of not expressed transcripts) and an 80% power. This estimate assumed uniformity of drug response. However, double the number was desirable for higher significance and considering correlation with baseline expression and response.</p>
                </sec>
              </sec>
              <sec id="sec3.5">
                <title>Data and Software Availability</title>
                <p id="p0245">The RNASeq gene expression data reported in this paper have been reported in Mendeley data with address <ext-link ext-link-type="uri" xlink:href="http://dx.doi.org/10.17632/cytrpb62f2.1" id="interref0010">http://dx.doi.org/10.17632/cytrpb62f2.1</ext-link>.</p>
              </sec>
              <sec id="sec3.6">
                <title>Additional Resources</title>
                <p id="p0250">ClinicalTrials.gov Identifier: <ext-link ext-link-type="ClinicalTrials.gov" xlink:href="NCT01266486" id="intref0045">NCT01266486</ext-link>.</p>
              </sec>
            </sec>
          </body>
          <back>
            <ref-list id="cebib0010">
              <title>References</title>
              <ref id="bib1">
                <element-citation publication-type="journal" id="sref1">
                  <person-group person-group-type="author">
                    <name>
                      <surname>Anders</surname>
                      <given-names>S.</given-names>
                    </name>
                    <name>
                      <surname>Huber</surname>
                      <given-names>W.</given-names>
                    </name>
                  </person-group>
                  <article-title>Differential expression analysis for sequence count data</article-title>
                  <source>Genome Biol.</source>
                  <volume>11</volume>
                  <year>2010</year>
                  <fpage>R106</fpage>
                  <pub-id pub-id-type="pmid">20979621</pub-id>
                </element-citation>
              </ref>
              <ref id="bib2">
                <element-citation publication-type="journal" id="sref2">
                  <person-group person-group-type="author">
                    <name>
                      <surname>Ben Sahra</surname>
                      <given-names>I.</given-names>
                    </name>
                    <name>
                      <surname>Laurent</surname>
                      <given-names>K.</given-names>
                    </name>
                    <name>
                      <surname>Giuliano</surname>
                      <given-names>S.</given-names>
                    </name>
                    <name>
                      <surname>Larbret</surname>
                      <given-names>F.</given-names>
                    </name>
                    <name>
                      <surname>Ponzio</surname>
                      <given-names>G.</given-names>
                    </name>
                    <name>
                      <surname>Gounon</surname>
                      <given-names>P.</given-names>
                    </name>
                    <name>
                      <surname>Le Marchand-Brustel</surname>
                      <given-names>Y.</given-names>
                    </name>
                    <name>
                      <surname>Giorgetti-Peraldi</surname>
                      <given-names>S.</given-names>
                    </name>
                    <name>
                      <surname>Cormont</surname>
                      <given-names>M.</given-names>
                    </name>
                    <name>
                      <surname>Bertolotto</surname>
                      <given-names>C.</given-names>
                    </name>
                  </person-group>
                  <article-title>Targeting cancer cell metabolism: the combination of metformin and 2-deoxyglucose induces p53-dependent apoptosis in prostate cancer cells</article-title>
                  <source>Cancer Res.</source>
                  <volume>70</volume>
                  <year>2010</year>
                  <fpage>2465</fpage>
                  <lpage>2475</lpage>
                  <pub-id pub-id-type="pmid">20215500</pub-id>
                </element-citation>
              </ref>
              <ref id="bib3">
                <element-citation publication-type="journal" id="sref3">
                  <person-group person-group-type="author">
                    <name>
                      <surname>Bertoldo</surname>
                      <given-names>A.</given-names>
                    </name>
                    <name>
                      <surname>Peltoniemi</surname>
                      <given-names>P.</given-names>
                    </name>
                    <name>
                      <surname>Oikonen</surname>
                      <given-names>V.</given-names>
                    </name>
                    <name>
                      <surname>Knuuti</surname>
                      <given-names>J.</given-names>
                    </name>
                    <name>
                      <surname>Nuutila</surname>
                      <given-names>P.</given-names>
                    </name>
                    <name>
                      <surname>Cobelli</surname>
                      <given-names>C.</given-names>
                    </name>
                  </person-group>
                  <article-title>Kinetic modeling of [(18)F]FDG in skeletal muscle by PET: a four-compartment five-rate-constant model</article-title>
                  <source>Am. J. Physiol. Endocrinol. Metab.</source>
                  <volume>281</volume>
                  <year>2001</year>
                  <fpage>E524</fpage>
                  <lpage>E536</lpage>
                  <pub-id pub-id-type="pmid">11500308</pub-id>
                </element-citation>
              </ref>
              <ref id="bib4">
                <element-citation publication-type="journal" id="sref4">
                  <person-group person-group-type="author">
                    <name>
                      <surname>Birsoy</surname>
                      <given-names>K.</given-names>
                    </name>
                    <name>
                      <surname>Possemato</surname>
                      <given-names>R.</given-names>
                    </name>
                    <name>
                      <surname>Lorbeer</surname>
                      <given-names>F.K.</given-names>
                    </name>
                    <name>
                      <surname>Bayraktar</surname>
                      <given-names>E.C.</given-names>
                    </name>
                    <name>
                      <surname>Thiru</surname>
                      <given-names>P.</given-names>
                    </name>
                    <name>
                      <surname>Yucel</surname>
                      <given-names>B.</given-names>
                    </name>
                    <name>
                      <surname>Wang</surname>
                      <given-names>T.</given-names>
                    </name>
                    <name>
                      <surname>Chen</surname>
                      <given-names>W.W.</given-names>
                    </name>
                    <name>
                      <surname>Clish</surname>
                      <given-names>C.B.</given-names>
                    </name>
                    <name>
                      <surname>Sabatini</surname>
                      <given-names>D.M.</given-names>
                    </name>
                  </person-group>
                  <article-title>Metabolic determinants of cancer cell sensitivity to glucose limitation and biguanides</article-title>
                  <source>Nature</source>
                  <volume>508</volume>
                  <year>2014</year>
                  <fpage>108</fpage>
                  <lpage>112</lpage>
                  <pub-id pub-id-type="pmid">24670634</pub-id>
                </element-citation>
              </ref>
              <ref id="bib5">
                <element-citation publication-type="journal" id="sref5">
                  <person-group person-group-type="author">
                    <name>
                      <surname>Birsoy</surname>
                      <given-names>K.</given-names>
                    </name>
                    <name>
                      <surname>Wang</surname>
                      <given-names>T.</given-names>
                    </name>
                    <name>
                      <surname>Chen</surname>
                      <given-names>W.W.</given-names>
                    </name>
                    <name>
                      <surname>Freinkman</surname>
                      <given-names>E.</given-names>
                    </name>
                    <name>
                      <surname>Abu-Remaileh</surname>
                      <given-names>M.</given-names>
                    </name>
                    <name>
                      <surname>Sabatini</surname>
                      <given-names>D.M.</given-names>
                    </name>
                  </person-group>
                  <article-title>An essential role of the mitochondrial electron transport chain in cell proliferation is to enable aspartate synthesis</article-title>
                  <source>Cell</source>
                  <volume>162</volume>
                  <year>2015</year>
                  <fpage>540</fpage>
                  <lpage>551</lpage>
                  <pub-id pub-id-type="pmid">26232224</pub-id>
                </element-citation>
              </ref>
              <ref id="bib6">
                <element-citation publication-type="journal" id="sref6">
                  <person-group person-group-type="author">
                    <name>
                      <surname>Bos</surname>
                      <given-names>R.</given-names>
                    </name>
                    <name>
                      <surname>van Der Hoeven</surname>
                      <given-names>J.J.</given-names>
                    </name>
                    <name>
                      <surname>van Der Wall</surname>
                      <given-names>E.</given-names>
                    </name>
                    <name>
                      <surname>van Der Groep</surname>
                      <given-names>P.</given-names>
                    </name>
                    <name>
                      <surname>van Diest</surname>
                      <given-names>P.J.</given-names>
                    </name>
                    <name>
                      <surname>Comans</surname>
                      <given-names>E.F.</given-names>
                    </name>
                    <name>
                      <surname>Joshi</surname>
                      <given-names>U.</given-names>
                    </name>
                    <name>
                      <surname>Semenza</surname>
                      <given-names>G.L.</given-names>
                    </name>
                    <name>
                      <surname>Hoekstra</surname>
                      <given-names>O.S.</given-names>
                    </name>
                    <name>
                      <surname>Lammertsma</surname>
                      <given-names>A.A.</given-names>
                    </name>
                  </person-group>
                  <article-title>Biologic correlates of (18)fluorodeoxyglucose uptake in human breast cancer measured by positron emission tomography</article-title>
                  <source>J. Clin. Oncol.</source>
                  <volume>20</volume>
                  <year>2002</year>
                  <fpage>379</fpage>
                  <lpage>387</lpage>
                  <pub-id pub-id-type="pmid">11786564</pub-id>
                </element-citation>
              </ref>
              <ref id="bib7">
                <element-citation publication-type="journal" id="sref7">
                  <person-group person-group-type="author">
                    <name>
                      <surname>Cardaci</surname>
                      <given-names>S.</given-names>
                    </name>
                    <name>
                      <surname>Zheng</surname>
                      <given-names>L.</given-names>
                    </name>
                    <name>
                      <surname>MacKay</surname>
                      <given-names>G.</given-names>
                    </name>
                    <name>
                      <surname>van den Broek</surname>
                      <given-names>N.J.</given-names>
                    </name>
                    <name>
                      <surname>MacKenzie</surname>
                      <given-names>E.D.</given-names>
                    </name>
                    <name>
                      <surname>Nixon</surname>
                      <given-names>C.</given-names>
                    </name>
                    <name>
                      <surname>Stevenson</surname>
                      <given-names>D.</given-names>
                    </name>
                    <name>
                      <surname>Tumanov</surname>
                      <given-names>S.</given-names>
                    </name>
                    <name>
                      <surname>Bulusu</surname>
                      <given-names>V.</given-names>
                    </name>
                    <name>
                      <surname>Kamphorst</surname>
                      <given-names>J.J.</given-names>
                    </name>
                  </person-group>
                  <article-title>Pyruvate carboxylation enables growth of SDH-deficient cells by supporting aspartate biosynthesis</article-title>
                  <source>Nat. Cell Biol.</source>
                  <volume>17</volume>
                  <year>2015</year>
                  <fpage>1317</fpage>
                  <lpage>1326</lpage>
                  <pub-id pub-id-type="pmid">26302408</pub-id>
                </element-citation>
              </ref>
              <ref id="bib8">
                <element-citation publication-type="journal" id="sref8">
                  <person-group person-group-type="author">
                    <name>
                      <surname>Chae</surname>
                      <given-names>Y.C.</given-names>
                    </name>
                    <name>
                      <surname>Vaira</surname>
                      <given-names>V.</given-names>
                    </name>
                    <name>
                      <surname>Caino</surname>
                      <given-names>M.C.</given-names>
                    </name>
                    <name>
                      <surname>Tang</surname>
                      <given-names>H.Y.</given-names>
                    </name>
                    <name>
                      <surname>Seo</surname>
                      <given-names>J.H.</given-names>
                    </name>
                    <name>
                      <surname>Kossenkov</surname>
                      <given-names>A.V.</given-names>
                    </name>
                    <name>
                      <surname>Ottobrini</surname>
                      <given-names>L.</given-names>
                    </name>
                    <name>
                      <surname>Martelli</surname>
                      <given-names>C.</given-names>
                    </name>
                    <name>
                      <surname>Lucignani</surname>
                      <given-names>G.</given-names>
                    </name>
                    <name>
                      <surname>Bertolini</surname>
                      <given-names>I.</given-names>
                    </name>
                  </person-group>
                  <article-title>Mitochondrial Akt regulation of hypoxic tumor reprogramming</article-title>
                  <source>Cancer Cell</source>
                  <volume>30</volume>
                  <year>2016</year>
                  <fpage>257</fpage>
                  <lpage>272</lpage>
                  <pub-id pub-id-type="pmid">27505672</pub-id>
                </element-citation>
              </ref>
              <ref id="bib9">
                <element-citation publication-type="journal" id="sref9">
                  <person-group person-group-type="author">
                    <name>
                      <surname>Chandel</surname>
                      <given-names>N.S.</given-names>
                    </name>
                    <name>
                      <surname>Avizonis</surname>
                      <given-names>D.</given-names>
                    </name>
                    <name>
                      <surname>Reczek</surname>
                      <given-names>C.R.</given-names>
                    </name>
                    <name>
                      <surname>Weinberg</surname>
                      <given-names>S.E.</given-names>
                    </name>
                    <name>
                      <surname>Menz</surname>
                      <given-names>S.</given-names>
                    </name>
                    <name>
                      <surname>Neuhaus</surname>
                      <given-names>R.</given-names>
                    </name>
                    <name>
                      <surname>Christian</surname>
                      <given-names>S.</given-names>
                    </name>
                    <name>
                      <surname>Haegebarth</surname>
                      <given-names>A.</given-names>
                    </name>
                    <name>
                      <surname>Algire</surname>
                      <given-names>C.</given-names>
                    </name>
                    <name>
                      <surname>Pollak</surname>
                      <given-names>M.</given-names>
                    </name>
                  </person-group>
                  <article-title>Are metformin doses used in murine cancer models clinically relevant?</article-title>
                  <source>Cell Metab.</source>
                  <volume>23</volume>
                  <year>2016</year>
                  <fpage>569</fpage>
                  <lpage>570</lpage>
                  <pub-id pub-id-type="pmid">27076070</pub-id>
                </element-citation>
              </ref>
              <ref id="bib10">
                <element-citation publication-type="journal" id="sref10">
                  <person-group person-group-type="author">
                    <name>
                      <surname>Chen</surname>
                      <given-names>W.W.</given-names>
                    </name>
                    <name>
                      <surname>Freinkman</surname>
                      <given-names>E.</given-names>
                    </name>
                    <name>
                      <surname>Wang</surname>
                      <given-names>T.</given-names>
                    </name>
                    <name>
                      <surname>Birsoy</surname>
                      <given-names>K.</given-names>
                    </name>
                    <name>
                      <surname>Sabatini</surname>
                      <given-names>D.M.</given-names>
                    </name>
                  </person-group>
                  <article-title>Absolute quantification of matrix metabolites reveals the dynamics of mitochondrial metabolism</article-title>
                  <source>Cell</source>
                  <volume>166</volume>
                  <year>2016</year>
                  <fpage>1324</fpage>
                  <lpage>1337.e11</lpage>
                  <pub-id pub-id-type="pmid">27565352</pub-id>
                </element-citation>
              </ref>
              <ref id="bib11">
                <element-citation publication-type="journal" id="sref11">
                  <person-group person-group-type="author">
                    <name>
                      <surname>Desmedt</surname>
                      <given-names>C.</given-names>
                    </name>
                    <name>
                      <surname>Haibe-Kains</surname>
                      <given-names>B.</given-names>
                    </name>
                    <name>
                      <surname>Wirapati</surname>
                      <given-names>P.</given-names>
                    </name>
                    <name>
                      <surname>Buyse</surname>
                      <given-names>M.</given-names>
                    </name>
                    <name>
                      <surname>Larsimont</surname>
                      <given-names>D.</given-names>
                    </name>
                    <name>
                      <surname>Bontempi</surname>
                      <given-names>G.</given-names>
                    </name>
                    <name>
                      <surname>Delorenzi</surname>
                      <given-names>M.</given-names>
                    </name>
                    <name>
                      <surname>Piccart</surname>
                      <given-names>M.</given-names>
                    </name>
                    <name>
                      <surname>Sotiriou</surname>
                      <given-names>C.</given-names>
                    </name>
                  </person-group>
                  <article-title>Biological processes associated with breast cancer clinical outcome depend on the molecular subtypes</article-title>
                  <source>Clin. Cancer Res.</source>
                  <volume>14</volume>
                  <year>2008</year>
                  <fpage>5158</fpage>
                  <lpage>5165</lpage>
                  <pub-id pub-id-type="pmid">18698033</pub-id>
                </element-citation>
              </ref>
              <ref id="bib12">
                <element-citation publication-type="journal" id="sref12">
                  <person-group person-group-type="author">
                    <name>
                      <surname>Dowling</surname>
                      <given-names>R.J.</given-names>
                    </name>
                    <name>
                      <surname>Lam</surname>
                      <given-names>S.</given-names>
                    </name>
                    <name>
                      <surname>Bassi</surname>
                      <given-names>C.</given-names>
                    </name>
                    <name>
                      <surname>Mouaaz</surname>
                      <given-names>S.</given-names>
                    </name>
                    <name>
                      <surname>Aman</surname>
                      <given-names>A.</given-names>
                    </name>
                    <name>
                      <surname>Kiyota</surname>
                      <given-names>T.</given-names>
                    </name>
                    <name>
                      <surname>Al-Awar</surname>
                      <given-names>R.</given-names>
                    </name>
                    <name>
                      <surname>Goodwin</surname>
                      <given-names>P.J.</given-names>
                    </name>
                    <name>
                      <surname>Stambolic</surname>
                      <given-names>V.</given-names>
                    </name>
                  </person-group>
                  <article-title>Metformin pharmacokinetics in mouse tumors: implications for human therapy</article-title>
                  <source>Cell Metab.</source>
                  <volume>23</volume>
                  <year>2016</year>
                  <fpage>567</fpage>
                  <lpage>568</lpage>
                  <pub-id pub-id-type="pmid">27076069</pub-id>
                </element-citation>
              </ref>
              <ref id="bib13">
                <element-citation publication-type="journal" id="sref13">
                  <person-group person-group-type="author">
                    <name>
                      <surname>Dowling</surname>
                      <given-names>R.J.</given-names>
                    </name>
                    <name>
                      <surname>Niraula</surname>
                      <given-names>S.</given-names>
                    </name>
                    <name>
                      <surname>Chang</surname>
                      <given-names>M.C.</given-names>
                    </name>
                    <name>
                      <surname>Done</surname>
                      <given-names>S.J.</given-names>
                    </name>
                    <name>
                      <surname>Ennis</surname>
                      <given-names>M.</given-names>
                    </name>
                    <name>
                      <surname>McCready</surname>
                      <given-names>D.R.</given-names>
                    </name>
                    <name>
                      <surname>Leong</surname>
                      <given-names>W.L.</given-names>
                    </name>
                    <name>
                      <surname>Escallon</surname>
                      <given-names>J.M.</given-names>
                    </name>
                    <name>
                      <surname>Reedijk</surname>
                      <given-names>M.</given-names>
                    </name>
                    <name>
                      <surname>Goodwin</surname>
                      <given-names>P.J.</given-names>
                    </name>
                  </person-group>
                  <article-title>Changes in insulin receptor signaling underlie neoadjuvant metformin administration in breast cancer: a prospective window of opportunity neoadjuvant study</article-title>
                  <source>Breast Cancer Res.</source>
                  <volume>17</volume>
                  <year>2015</year>
                  <fpage>32</fpage>
                  <pub-id pub-id-type="pmid">25849721</pub-id>
                </element-citation>
              </ref>
              <ref id="bib14">
                <element-citation publication-type="journal" id="sref14">
                  <person-group person-group-type="author">
                    <name>
                      <surname>Dowling</surname>
                      <given-names>R.J.</given-names>
                    </name>
                    <name>
                      <surname>Niraula</surname>
                      <given-names>S.</given-names>
                    </name>
                    <name>
                      <surname>Stambolic</surname>
                      <given-names>V.</given-names>
                    </name>
                    <name>
                      <surname>Goodwin</surname>
                      <given-names>P.J.</given-names>
                    </name>
                  </person-group>
                  <article-title>Metformin in cancer: translational challenges</article-title>
                  <source>J. Mol. Endocrinol.</source>
                  <volume>48</volume>
                  <year>2012</year>
                  <fpage>R31</fpage>
                  <lpage>R43</lpage>
                  <pub-id pub-id-type="pmid">22355097</pub-id>
                </element-citation>
              </ref>
              <ref id="bib15">
                <element-citation publication-type="journal" id="sref15">
                  <person-group person-group-type="author">
                    <name>
                      <surname>Dunnwald</surname>
                      <given-names>L.K.</given-names>
                    </name>
                    <name>
                      <surname>Doot</surname>
                      <given-names>R.K.</given-names>
                    </name>
                    <name>
                      <surname>Specht</surname>
                      <given-names>J.M.</given-names>
                    </name>
                    <name>
                      <surname>Gralow</surname>
                      <given-names>J.R.</given-names>
                    </name>
                    <name>
                      <surname>Ellis</surname>
                      <given-names>G.K.</given-names>
                    </name>
                    <name>
                      <surname>Livingston</surname>
                      <given-names>R.B.</given-names>
                    </name>
                    <name>
                      <surname>Linden</surname>
                      <given-names>H.M.</given-names>
                    </name>
                    <name>
                      <surname>Gadi</surname>
                      <given-names>V.K.</given-names>
                    </name>
                    <name>
                      <surname>Kurland</surname>
                      <given-names>B.F.</given-names>
                    </name>
                    <name>
                      <surname>Schubert</surname>
                      <given-names>E.K.</given-names>
                    </name>
                  </person-group>
                  <article-title>PET tumor metabolism in locally advanced breast cancer patients undergoing neoadjuvant chemotherapy: value of static versus kinetic measures of fluorodeoxyglucose uptake</article-title>
                  <source>Clin. Cancer Res.</source>
                  <volume>17</volume>
                  <year>2011</year>
                  <fpage>2400</fpage>
                  <lpage>2409</lpage>
                  <pub-id pub-id-type="pmid">21364034</pub-id>
                </element-citation>
              </ref>
              <ref id="bib16">
                <element-citation publication-type="journal" id="sref16">
                  <person-group person-group-type="author">
                    <name>
                      <surname>Fendt</surname>
                      <given-names>S.M.</given-names>
                    </name>
                    <name>
                      <surname>Bell</surname>
                      <given-names>E.L.</given-names>
                    </name>
                    <name>
                      <surname>Keibler</surname>
                      <given-names>M.A.</given-names>
                    </name>
                    <name>
                      <surname>Davidson</surname>
                      <given-names>S.M.</given-names>
                    </name>
                    <name>
                      <surname>Wirth</surname>
                      <given-names>G.J.</given-names>
                    </name>
                    <name>
                      <surname>Fiske</surname>
                      <given-names>B.</given-names>
                    </name>
                    <name>
                      <surname>Mayers</surname>
                      <given-names>J.R.</given-names>
                    </name>
                    <name>
                      <surname>Schwab</surname>
                      <given-names>M.</given-names>
                    </name>
                    <name>
                      <surname>Bellinger</surname>
                      <given-names>G.</given-names>
                    </name>
                    <name>
                      <surname>Csibi</surname>
                      <given-names>A.</given-names>
                    </name>
                  </person-group>
                  <article-title>Metformin decreases glucose oxidation and increases the dependency of prostate cancer cells on reductive glutamine metabolism</article-title>
                  <source>Cancer Res.</source>
                  <volume>73</volume>
                  <year>2013</year>
                  <fpage>4429</fpage>
                  <lpage>4438</lpage>
                  <pub-id pub-id-type="pmid">23687346</pub-id>
                </element-citation>
              </ref>
              <ref id="bib17">
                <element-citation publication-type="journal" id="sref17">
                  <person-group person-group-type="author">
                    <name>
                      <surname>Gaude</surname>
                      <given-names>E.</given-names>
                    </name>
                    <name>
                      <surname>Schmidt</surname>
                      <given-names>C.</given-names>
                    </name>
                    <name>
                      <surname>Gammage</surname>
                      <given-names>P.A.</given-names>
                    </name>
                    <name>
                      <surname>Dugourd</surname>
                      <given-names>A.</given-names>
                    </name>
                    <name>
                      <surname>Blacker</surname>
                      <given-names>T.</given-names>
                    </name>
                    <name>
                      <surname>Chew</surname>
                      <given-names>S.P.</given-names>
                    </name>
                    <name>
                      <surname>Saez-Rodriguez</surname>
                      <given-names>J.</given-names>
                    </name>
                    <name>
                      <surname>O'Neill</surname>
                      <given-names>J.S.</given-names>
                    </name>
                    <name>
                      <surname>Szabadkai</surname>
                      <given-names>G.</given-names>
                    </name>
                    <name>
                      <surname>Minczuk</surname>
                      <given-names>M.</given-names>
                    </name>
                  </person-group>
                  <article-title>NADH shuttling couples cytosolic reductive carboxylation of glutamine with glycolysis in cells with mitochondrial dysfunction</article-title>
                  <source>Mol. Cell</source>
                  <volume>69</volume>
                  <year>2018</year>
                  <fpage>581</fpage>
                  <lpage>593.e7</lpage>
                  <pub-id pub-id-type="pmid">29452638</pub-id>
                </element-citation>
              </ref>
              <ref id="bib18">
                <element-citation publication-type="journal" id="sref18">
                  <person-group person-group-type="author">
                    <name>
                      <surname>Gillessen</surname>
                      <given-names>S.</given-names>
                    </name>
                    <name>
                      <surname>Gilson</surname>
                      <given-names>C.</given-names>
                    </name>
                    <name>
                      <surname>James</surname>
                      <given-names>N.</given-names>
                    </name>
                    <name>
                      <surname>Adler</surname>
                      <given-names>A.</given-names>
                    </name>
                    <name>
                      <surname>Sydes</surname>
                      <given-names>M.R.</given-names>
                    </name>
                    <name>
                      <surname>Clarke</surname>
                      <given-names>N.</given-names>
                    </name>
                    <collab>STAMPEDE Trial Management Group</collab>
                  </person-group>
                  <article-title>Repurposing metformin as therapy for prostate cancer within the STAMPEDE trial platform</article-title>
                  <source>Eur. Urol.</source>
                  <volume>70</volume>
                  <year>2016</year>
                  <fpage>906</fpage>
                  <lpage>908</lpage>
                  <pub-id pub-id-type="pmid">27450106</pub-id>
                </element-citation>
              </ref>
              <ref id="bib19">
                <element-citation publication-type="journal" id="sref19">
                  <person-group person-group-type="author">
                    <name>
                      <surname>Goodwin</surname>
                      <given-names>P.J.</given-names>
                    </name>
                    <name>
                      <surname>Parulekar</surname>
                      <given-names>W.R.</given-names>
                    </name>
                    <name>
                      <surname>Gelmon</surname>
                      <given-names>K.A.</given-names>
                    </name>
                    <name>
                      <surname>Shepherd</surname>
                      <given-names>L.E.</given-names>
                    </name>
                    <name>
                      <surname>Ligibel</surname>
                      <given-names>J.A.</given-names>
                    </name>
                    <name>
                      <surname>Hershman</surname>
                      <given-names>D.L.</given-names>
                    </name>
                    <name>
                      <surname>Rastogi</surname>
                      <given-names>P.</given-names>
                    </name>
                    <name>
                      <surname>Mayer</surname>
                      <given-names>I.A.</given-names>
                    </name>
                    <name>
                      <surname>Hobday</surname>
                      <given-names>T.J.</given-names>
                    </name>
                    <name>
                      <surname>Lemieux</surname>
                      <given-names>J.</given-names>
                    </name>
                  </person-group>
                  <article-title>Effect of metformin vs placebo on and metabolic factors in NCIC CTG MA.32</article-title>
                  <source>J. Natl. Cancer Inst.</source>
                  <volume>107</volume>
                  <year>2015</year>
                </element-citation>
              </ref>
              <ref id="bib20">
                <element-citation publication-type="journal" id="sref20">
                  <person-group person-group-type="author">
                    <name>
                      <surname>Hadad</surname>
                      <given-names>S.</given-names>
                    </name>
                    <name>
                      <surname>Iwamoto</surname>
                      <given-names>T.</given-names>
                    </name>
                    <name>
                      <surname>Jordan</surname>
                      <given-names>L.</given-names>
                    </name>
                    <name>
                      <surname>Purdie</surname>
                      <given-names>C.</given-names>
                    </name>
                    <name>
                      <surname>Bray</surname>
                      <given-names>S.</given-names>
                    </name>
                    <name>
                      <surname>Baker</surname>
                      <given-names>L.</given-names>
                    </name>
                    <name>
                      <surname>Jellema</surname>
                      <given-names>G.</given-names>
                    </name>
                    <name>
                      <surname>Deharo</surname>
                      <given-names>S.</given-names>
                    </name>
                    <name>
                      <surname>Hardie</surname>
                      <given-names>D.G.</given-names>
                    </name>
                    <name>
                      <surname>Pusztai</surname>
                      <given-names>L.</given-names>
                    </name>
                  </person-group>
                  <article-title>Evidence for biological effects of metformin in operable breast cancer: a pre-operative, window-of-opportunity, randomized trial</article-title>
                  <source>Breast Cancer Res. Treat.</source>
                  <volume>128</volume>
                  <year>2011</year>
                  <fpage>783</fpage>
                  <lpage>794</lpage>
                  <pub-id pub-id-type="pmid">21655990</pub-id>
                </element-citation>
              </ref>
              <ref id="bib21">
                <element-citation publication-type="journal" id="sref21">
                  <person-group person-group-type="author">
                    <name>
                      <surname>Haugrud</surname>
                      <given-names>A.B.</given-names>
                    </name>
                    <name>
                      <surname>Zhuang</surname>
                      <given-names>Y.</given-names>
                    </name>
                    <name>
                      <surname>Coppock</surname>
                      <given-names>J.D.</given-names>
                    </name>
                    <name>
                      <surname>Miskimins</surname>
                      <given-names>W.K.</given-names>
                    </name>
                  </person-group>
                  <article-title>Dichloroacetate enhances apoptotic cell death via oxidative damage and attenuates lactate production in metformin-treated breast cancer cells</article-title>
                  <source>Breast Cancer Res. Treat.</source>
                  <volume>147</volume>
                  <year>2014</year>
                  <fpage>539</fpage>
                  <lpage>550</lpage>
                  <pub-id pub-id-type="pmid">25212175</pub-id>
                </element-citation>
              </ref>
              <ref id="bib22">
                <element-citation publication-type="journal" id="sref22">
                  <person-group person-group-type="author">
                    <name>
                      <surname>Hume</surname>
                      <given-names>R.</given-names>
                    </name>
                  </person-group>
                  <article-title>Prediction of lean body mass from height and weight</article-title>
                  <source>J. Clin. Pathol.</source>
                  <volume>19</volume>
                  <year>1966</year>
                  <fpage>389</fpage>
                  <lpage>391</lpage>
                  <pub-id pub-id-type="pmid">5929341</pub-id>
                </element-citation>
              </ref>
              <ref id="bib23">
                <element-citation publication-type="journal" id="sref23">
                  <person-group person-group-type="author">
                    <name>
                      <surname>Joshua</surname>
                      <given-names>A.M.</given-names>
                    </name>
                    <name>
                      <surname>Zannella</surname>
                      <given-names>V.E.</given-names>
                    </name>
                    <name>
                      <surname>Downes</surname>
                      <given-names>M.R.</given-names>
                    </name>
                    <name>
                      <surname>Bowes</surname>
                      <given-names>B.</given-names>
                    </name>
                    <name>
                      <surname>Hersey</surname>
                      <given-names>K.</given-names>
                    </name>
                    <name>
                      <surname>Koritzinsky</surname>
                      <given-names>M.</given-names>
                    </name>
                    <name>
                      <surname>Schwab</surname>
                      <given-names>M.</given-names>
                    </name>
                    <name>
                      <surname>Hofmann</surname>
                      <given-names>U.</given-names>
                    </name>
                    <name>
                      <surname>Evans</surname>
                      <given-names>A.</given-names>
                    </name>
                    <name>
                      <surname>van der Kwast</surname>
                      <given-names>T.</given-names>
                    </name>
                  </person-group>
                  <article-title>A pilot 'window of opportunity' neoadjuvant study of metformin in localised prostate cancer</article-title>
                  <source>Prostate Cancer Prostatic Dis.</source>
                  <volume>17</volume>
                  <year>2014</year>
                  <fpage>252</fpage>
                  <lpage>258</lpage>
                  <pub-id pub-id-type="pmid">24861559</pub-id>
                </element-citation>
              </ref>
              <ref id="bib24">
                <element-citation publication-type="journal" id="sref24">
                  <person-group person-group-type="author">
                    <name>
                      <surname>Laskov</surname>
                      <given-names>I.</given-names>
                    </name>
                    <name>
                      <surname>Drudi</surname>
                      <given-names>L.</given-names>
                    </name>
                    <name>
                      <surname>Beauchamp</surname>
                      <given-names>M.C.</given-names>
                    </name>
                    <name>
                      <surname>Yasmeen</surname>
                      <given-names>A.</given-names>
                    </name>
                    <name>
                      <surname>Ferenczy</surname>
                      <given-names>A.</given-names>
                    </name>
                    <name>
                      <surname>Pollak</surname>
                      <given-names>M.</given-names>
                    </name>
                    <name>
                      <surname>Gotlieb</surname>
                      <given-names>W.H.</given-names>
                    </name>
                  </person-group>
                  <article-title>Anti-diabetic doses of metformin decrease proliferation markers in tumors of patients with endometrial cancer</article-title>
                  <source>Gynecol. Oncol.</source>
                  <volume>134</volume>
                  <year>2014</year>
                  <fpage>607</fpage>
                  <lpage>614</lpage>
                  <pub-id pub-id-type="pmid">24972190</pub-id>
                </element-citation>
              </ref>
              <ref id="bib25">
                <element-citation publication-type="journal" id="sref25">
                  <person-group person-group-type="author">
                    <name>
                      <surname>Liu</surname>
                      <given-names>D.</given-names>
                    </name>
                    <name>
                      <surname>Chalkidou</surname>
                      <given-names>A.</given-names>
                    </name>
                    <name>
                      <surname>Landau</surname>
                      <given-names>D.B.</given-names>
                    </name>
                    <name>
                      <surname>Marsden</surname>
                      <given-names>P.K.</given-names>
                    </name>
                    <name>
                      <surname>Fenwick</surname>
                      <given-names>J.D.</given-names>
                    </name>
                  </person-group>
                  <article-title>18F-FLT uptake kinetics in head and neck squamous cell carcinoma: a PET imaging study</article-title>
                  <source>Med. Phys.</source>
                  <volume>41</volume>
                  <year>2014</year>
                  <fpage>041911</fpage>
                  <pub-id pub-id-type="pmid">24694142</pub-id>
                </element-citation>
              </ref>
              <ref id="bib26">
                <element-citation publication-type="journal" id="sref26">
                  <person-group person-group-type="author">
                    <name>
                      <surname>Liu</surname>
                      <given-names>X.</given-names>
                    </name>
                    <name>
                      <surname>Romero</surname>
                      <given-names>I.L.</given-names>
                    </name>
                    <name>
                      <surname>Litchfield</surname>
                      <given-names>L.M.</given-names>
                    </name>
                    <name>
                      <surname>Lengyel</surname>
                      <given-names>E.</given-names>
                    </name>
                    <name>
                      <surname>Locasale</surname>
                      <given-names>J.W.</given-names>
                    </name>
                  </person-group>
                  <article-title>Metformin targets central carbon metabolism and reveals mitochondrial requirements in human cancers</article-title>
                  <source>Cell Metab.</source>
                  <volume>24</volume>
                  <year>2016</year>
                  <fpage>728</fpage>
                  <lpage>739</lpage>
                  <pub-id pub-id-type="pmid">27746051</pub-id>
                </element-citation>
              </ref>
              <ref id="bib27">
                <element-citation publication-type="journal" id="sref27">
                  <person-group person-group-type="author">
                    <name>
                      <surname>McCarthy</surname>
                      <given-names>D.J.</given-names>
                    </name>
                    <name>
                      <surname>Chen</surname>
                      <given-names>Y.</given-names>
                    </name>
                    <name>
                      <surname>Smyth</surname>
                      <given-names>G.K.</given-names>
                    </name>
                  </person-group>
                  <article-title>Differential expression analysis of multifactor RNA-Seq experiments with respect to biological variation</article-title>
                  <source>Nucleic Acids Res.</source>
                  <volume>40</volume>
                  <year>2012</year>
                  <fpage>4288</fpage>
                  <lpage>4297</lpage>
                  <pub-id pub-id-type="pmid">22287627</pub-id>
                </element-citation>
              </ref>
              <ref id="bib28">
                <element-citation publication-type="journal" id="sref28">
                  <person-group person-group-type="author">
                    <name>
                      <surname>Mehta</surname>
                      <given-names>S.</given-names>
                    </name>
                    <name>
                      <surname>Hughes</surname>
                      <given-names>N.P.</given-names>
                    </name>
                    <name>
                      <surname>Li</surname>
                      <given-names>S.</given-names>
                    </name>
                    <name>
                      <surname>Jubb</surname>
                      <given-names>A.</given-names>
                    </name>
                    <name>
                      <surname>Adams</surname>
                      <given-names>R.</given-names>
                    </name>
                    <name>
                      <surname>Lord</surname>
                      <given-names>S.</given-names>
                    </name>
                    <name>
                      <surname>Koumakis</surname>
                      <given-names>L.</given-names>
                    </name>
                    <name>
                      <surname>van Stiphout</surname>
                      <given-names>R.</given-names>
                    </name>
                    <name>
                      <surname>Padhani</surname>
                      <given-names>A.</given-names>
                    </name>
                    <name>
                      <surname>Makris</surname>
                      <given-names>A.</given-names>
                    </name>
                  </person-group>
                  <article-title>Radiogenomics monitoring in breast cancer identifies metabolism and immune checkpoints as early actionable mechanisms of resistance to anti-angiogenic treatment</article-title>
                  <source>EBioMedicine</source>
                  <volume>10</volume>
                  <year>2016</year>
                  <fpage>109</fpage>
                  <lpage>116</lpage>
                  <pub-id pub-id-type="pmid">27474395</pub-id>
                </element-citation>
              </ref>
              <ref id="bib29">
                <element-citation publication-type="journal" id="sref29">
                  <person-group person-group-type="author">
                    <name>
                      <surname>Mitsuhashi</surname>
                      <given-names>A.</given-names>
                    </name>
                    <name>
                      <surname>Kiyokawa</surname>
                      <given-names>T.</given-names>
                    </name>
                    <name>
                      <surname>Sato</surname>
                      <given-names>Y.</given-names>
                    </name>
                    <name>
                      <surname>Shozu</surname>
                      <given-names>M.</given-names>
                    </name>
                  </person-group>
                  <article-title>Effects of metformin on endometrial cancer cell growth in vivo: a preoperative prospective trial</article-title>
                  <source>Cancer</source>
                  <volume>120</volume>
                  <year>2014</year>
                  <fpage>2986</fpage>
                  <lpage>2995</lpage>
                  <pub-id pub-id-type="pmid">24917306</pub-id>
                </element-citation>
              </ref>
              <ref id="bib30">
                <element-citation publication-type="journal" id="sref30">
                  <person-group person-group-type="author">
                    <name>
                      <surname>Mullen</surname>
                      <given-names>A.R.</given-names>
                    </name>
                    <name>
                      <surname>Wheaton</surname>
                      <given-names>W.W.</given-names>
                    </name>
                    <name>
                      <surname>Jin</surname>
                      <given-names>E.S.</given-names>
                    </name>
                    <name>
                      <surname>Chen</surname>
                      <given-names>P.H.</given-names>
                    </name>
                    <name>
                      <surname>Sullivan</surname>
                      <given-names>L.B.</given-names>
                    </name>
                    <name>
                      <surname>Cheng</surname>
                      <given-names>T.</given-names>
                    </name>
                    <name>
                      <surname>Yang</surname>
                      <given-names>Y.</given-names>
                    </name>
                    <name>
                      <surname>Linehan</surname>
                      <given-names>W.M.</given-names>
                    </name>
                    <name>
                      <surname>Chandel</surname>
                      <given-names>N.S.</given-names>
                    </name>
                    <name>
                      <surname>DeBerardinis</surname>
                      <given-names>R.J.</given-names>
                    </name>
                  </person-group>
                  <article-title>Reductive carboxylation supports growth in tumour cells with defective mitochondria</article-title>
                  <source>Nature</source>
                  <volume>481</volume>
                  <year>2011</year>
                  <fpage>385</fpage>
                  <lpage>388</lpage>
                  <pub-id pub-id-type="pmid">22101431</pub-id>
                </element-citation>
              </ref>
              <ref id="bib31">
                <element-citation publication-type="journal" id="sref31">
                  <person-group person-group-type="author">
                    <name>
                      <surname>Niraula</surname>
                      <given-names>S.</given-names>
                    </name>
                    <name>
                      <surname>Dowling</surname>
                      <given-names>R.J.</given-names>
                    </name>
                    <name>
                      <surname>Ennis</surname>
                      <given-names>M.</given-names>
                    </name>
                    <name>
                      <surname>Chang</surname>
                      <given-names>M.C.</given-names>
                    </name>
                    <name>
                      <surname>Done</surname>
                      <given-names>S.J.</given-names>
                    </name>
                    <name>
                      <surname>Hood</surname>
                      <given-names>N.</given-names>
                    </name>
                    <name>
                      <surname>Escallon</surname>
                      <given-names>J.</given-names>
                    </name>
                    <name>
                      <surname>Leong</surname>
                      <given-names>W.L.</given-names>
                    </name>
                    <name>
                      <surname>McCready</surname>
                      <given-names>D.R.</given-names>
                    </name>
                    <name>
                      <surname>Reedijk</surname>
                      <given-names>M.</given-names>
                    </name>
                  </person-group>
                  <article-title>Metformin in early breast cancer: a prospective window of opportunity neoadjuvant study</article-title>
                  <source>Breast Cancer Res. Treat.</source>
                  <volume>135</volume>
                  <year>2012</year>
                  <fpage>821</fpage>
                  <lpage>830</lpage>
                  <pub-id pub-id-type="pmid">22933030</pub-id>
                </element-citation>
              </ref>
              <ref id="bib32">
                <element-citation publication-type="journal" id="sref32">
                  <person-group person-group-type="author">
                    <name>
                      <surname>Robey</surname>
                      <given-names>R.B.</given-names>
                    </name>
                    <name>
                      <surname>Hay</surname>
                      <given-names>N.</given-names>
                    </name>
                  </person-group>
                  <article-title>Is Akt the “Warburg kinase”?-Akt-energy metabolism interactions and oncogenesis</article-title>
                  <source>Semin. Cancer Biol.</source>
                  <volume>19</volume>
                  <year>2009</year>
                  <fpage>25</fpage>
                  <lpage>31</lpage>
                  <pub-id pub-id-type="pmid">19130886</pub-id>
                </element-citation>
              </ref>
              <ref id="bib33">
                <element-citation publication-type="journal" id="sref33">
                  <person-group person-group-type="author">
                    <name>
                      <surname>Robinson</surname>
                      <given-names>M.D.</given-names>
                    </name>
                    <name>
                      <surname>McCarthy</surname>
                      <given-names>D.J.</given-names>
                    </name>
                    <name>
                      <surname>Smyth</surname>
                      <given-names>G.K.</given-names>
                    </name>
                  </person-group>
                  <article-title>edgeR: a Bioconductor package for differential expression analysis of digital gene expression data</article-title>
                  <source>Bioinformatics</source>
                  <volume>26</volume>
                  <year>2010</year>
                  <fpage>139</fpage>
                  <lpage>140</lpage>
                  <pub-id pub-id-type="pmid">19910308</pub-id>
                </element-citation>
              </ref>
              <ref id="bib34">
                <element-citation publication-type="journal" id="sref34">
                  <person-group person-group-type="author">
                    <name>
                      <surname>Schooneman</surname>
                      <given-names>M.G.</given-names>
                    </name>
                    <name>
                      <surname>Vaz</surname>
                      <given-names>F.M.</given-names>
                    </name>
                    <name>
                      <surname>Houten</surname>
                      <given-names>S.M.</given-names>
                    </name>
                    <name>
                      <surname>Soeters</surname>
                      <given-names>M.R.</given-names>
                    </name>
                  </person-group>
                  <article-title>Acylcarnitines: reflecting or inflicting insulin resistance?</article-title>
                  <source>Diabetes</source>
                  <volume>62</volume>
                  <year>2013</year>
                  <fpage>1</fpage>
                  <lpage>8</lpage>
                  <pub-id pub-id-type="pmid">23258903</pub-id>
                </element-citation>
              </ref>
              <ref id="bib35">
                <element-citation publication-type="journal" id="sref35">
                  <person-group person-group-type="author">
                    <name>
                      <surname>Schuler</surname>
                      <given-names>K.M.</given-names>
                    </name>
                    <name>
                      <surname>Rambally</surname>
                      <given-names>B.S.</given-names>
                    </name>
                    <name>
                      <surname>DiFurio</surname>
                      <given-names>M.J.</given-names>
                    </name>
                    <name>
                      <surname>Sampey</surname>
                      <given-names>B.P.</given-names>
                    </name>
                    <name>
                      <surname>Gehrig</surname>
                      <given-names>P.A.</given-names>
                    </name>
                    <name>
                      <surname>Makowski</surname>
                      <given-names>L.</given-names>
                    </name>
                    <name>
                      <surname>Bae-Jump</surname>
                      <given-names>V.L.</given-names>
                    </name>
                  </person-group>
                  <article-title>Antiproliferative and metabolic effects of metformin in a preoperative window clinical trial for endometrial cancer</article-title>
                  <source>Cancer Med.</source>
                  <volume>4</volume>
                  <year>2015</year>
                  <fpage>161</fpage>
                  <lpage>173</lpage>
                  <pub-id pub-id-type="pmid">25417601</pub-id>
                </element-citation>
              </ref>
              <ref id="bib36">
                <element-citation publication-type="journal" id="sref36">
                  <person-group person-group-type="author">
                    <name>
                      <surname>Sonnenblick</surname>
                      <given-names>A.</given-names>
                    </name>
                    <name>
                      <surname>Agbor-Tarh</surname>
                      <given-names>D.</given-names>
                    </name>
                    <name>
                      <surname>Bradbury</surname>
                      <given-names>I.</given-names>
                    </name>
                    <name>
                      <surname>Di Cosimo</surname>
                      <given-names>S.</given-names>
                    </name>
                    <name>
                      <surname>Azim</surname>
                      <given-names>H.A.</given-names>
                      <suffix>Jr.</suffix>
                    </name>
                    <name>
                      <surname>Fumagalli</surname>
                      <given-names>D.</given-names>
                    </name>
                    <name>
                      <surname>Sarp</surname>
                      <given-names>S.</given-names>
                    </name>
                    <name>
                      <surname>Wolff</surname>
                      <given-names>A.C.</given-names>
                    </name>
                    <name>
                      <surname>Andersson</surname>
                      <given-names>M.</given-names>
                    </name>
                    <name>
                      <surname>Kroep</surname>
                      <given-names>J.</given-names>
                    </name>
                  </person-group>
                  <article-title>Impact of diabetes, insulin, and metformin use on the outcome of patients with human epidermal growth factor receptor 2-positive primary breast cancer: analysis from the ALTTO phase III randomized trial</article-title>
                  <source>J. Clin. Oncol.</source>
                  <volume>35</volume>
                  <year>2017</year>
                  <fpage>1421</fpage>
                  <lpage>1429</lpage>
                  <pub-id pub-id-type="pmid">28375706</pub-id>
                </element-citation>
              </ref>
              <ref id="bib37">
                <element-citation publication-type="journal" id="sref37">
                  <person-group person-group-type="author">
                    <name>
                      <surname>Sullivan</surname>
                      <given-names>L.B.</given-names>
                    </name>
                    <name>
                      <surname>Gui</surname>
                      <given-names>D.Y.</given-names>
                    </name>
                    <name>
                      <surname>Hosios</surname>
                      <given-names>A.M.</given-names>
                    </name>
                    <name>
                      <surname>Bush</surname>
                      <given-names>L.N.</given-names>
                    </name>
                    <name>
                      <surname>Freinkman</surname>
                      <given-names>E.</given-names>
                    </name>
                    <name>
                      <surname>Vander Heiden</surname>
                      <given-names>M.G.</given-names>
                    </name>
                  </person-group>
                  <article-title>Supporting aspartate biosynthesis is an essential function of respiration in proliferating cells</article-title>
                  <source>Cell</source>
                  <volume>162</volume>
                  <year>2015</year>
                  <fpage>552</fpage>
                  <lpage>563</lpage>
                  <pub-id pub-id-type="pmid">26232225</pub-id>
                </element-citation>
              </ref>
              <ref id="bib38">
                <element-citation publication-type="journal" id="sref38">
                  <person-group person-group-type="author">
                    <name>
                      <surname>Wheaton</surname>
                      <given-names>W.W.</given-names>
                    </name>
                    <name>
                      <surname>Weinberg</surname>
                      <given-names>S.E.</given-names>
                    </name>
                    <name>
                      <surname>Hamanaka</surname>
                      <given-names>R.B.</given-names>
                    </name>
                    <name>
                      <surname>Soberanes</surname>
                      <given-names>S.</given-names>
                    </name>
                    <name>
                      <surname>Sullivan</surname>
                      <given-names>L.B.</given-names>
                    </name>
                    <name>
                      <surname>Anso</surname>
                      <given-names>E.</given-names>
                    </name>
                    <name>
                      <surname>Glasauer</surname>
                      <given-names>A.</given-names>
                    </name>
                    <name>
                      <surname>Dufour</surname>
                      <given-names>E.</given-names>
                    </name>
                    <name>
                      <surname>Mutlu</surname>
                      <given-names>G.M.</given-names>
                    </name>
                    <name>
                      <surname>Budigner</surname>
                      <given-names>G.S.</given-names>
                    </name>
                  </person-group>
                  <article-title>Metformin inhibits mitochondrial complex I of cancer cells to reduce tumorigenesis</article-title>
                  <source>Elife</source>
                  <volume>3</volume>
                  <year>2014</year>
                  <fpage>e02242</fpage>
                  <pub-id pub-id-type="pmid">24843020</pub-id>
                </element-citation>
              </ref>
              <ref id="bib39">
                <element-citation publication-type="journal" id="sref39">
                  <person-group person-group-type="author">
                    <name>
                      <surname>Zhang</surname>
                      <given-names>L.</given-names>
                    </name>
                    <name>
                      <surname>Han</surname>
                      <given-names>J.</given-names>
                    </name>
                    <name>
                      <surname>Jackson</surname>
                      <given-names>A.L.</given-names>
                    </name>
                    <name>
                      <surname>Clark</surname>
                      <given-names>L.N.</given-names>
                    </name>
                    <name>
                      <surname>Kilgore</surname>
                      <given-names>J.</given-names>
                    </name>
                    <name>
                      <surname>Guo</surname>
                      <given-names>H.</given-names>
                    </name>
                    <name>
                      <surname>Livingston</surname>
                      <given-names>N.</given-names>
                    </name>
                    <name>
                      <surname>Batchelor</surname>
                      <given-names>K.</given-names>
                    </name>
                    <name>
                      <surname>Yin</surname>
                      <given-names>Y.</given-names>
                    </name>
                    <name>
                      <surname>Gilliam</surname>
                      <given-names>T.P.</given-names>
                    </name>
                  </person-group>
                  <article-title>NT1014, a novel biguanide, inhibits ovarian cancer growth in vitro and in vivo</article-title>
                  <source>J. Hematol. Oncol.</source>
                  <volume>9</volume>
                  <year>2016</year>
                  <fpage>91</fpage>
                  <pub-id pub-id-type="pmid">27655410</pub-id>
                </element-citation>
              </ref>
            </ref-list>
            <sec id="app2" sec-type="supplementary-material">
              <title>Supplemental Information</title>
              <p id="p0275">
                <supplementary-material content-type="local-data" id="mmc1">
                  <caption>
                    <title>Document S1. Figures S1–S5 and Tables S1–S6</title>
                  </caption>
                  <media xlink:href="mmc1.pdf"/>
                </supplementary-material>
                <supplementary-material content-type="local-data" id="mmc2">
                  <caption>
                    <title>Document S2. Article plus Supplemental Information</title>
                  </caption>
                  <media xlink:href="mmc2.pdf"/>
                </supplementary-material>
              </p>
            </sec>
            <ack id="ack0010">
              <title>Acknowledgments</title>
              <p>Funding for this study was provided by the <funding-source id="gs1">Oxford Cancer Imaging Centre</funding-source> (funded by Cancer Research UK and the Engineering and Physical Sciences Research Council), the <funding-source id="gs2">NIHR Oxford Biomedical Research Centre</funding-source>, and the <funding-source id="gs3">Breast Cancer Research Foundation</funding-source>, while the work of C.F. and E.G. was funded by a core fund from the <funding-source id="gs4">Medical Research Council</funding-source>. The circulating glucose, insulin, c-peptide, and c-reactive protein assays were carried out by the Oxford Clinical Biochemistry Laboratory, circulating IL-6 and TNF-α assays by the Oxford Clinical Immunology Laboratory (both Oxford University Hospitals NHS Foundation Trust), and adiponectin and leptin by the Core Biochemical Assay Laboratory, Cambridge University Hospitals NHS Foundation Trust. The immunohistochemistry assays were carried out by the GCP laboratory, Department of Oncology, University of Oxford.</p>
              <sec id="sec4">
                <title>Author Contributions</title>
                <p id="p0260">S.R.L. and A.L.H. designed the study. S.R.L., A.M.T., and A.L.H. co-supervised the clinical implementation of the study. S.R.L., A.L.H., A.M.T., M.-L.A.-S., A.S., P.G.R., R.E., and R.F.A. recruited patients to the clinical trial, collected the clinical data, and carried out the study procedures. D.L., T.M., N.P., D.R.McG., K.B., F.G., L.B., and E.J.T. carried out the imaging analysis with overall supervision of the project from J.D.F. E.G. performed the metabolomics analyses of the clinical samples with supervision from C.F. S.R.L., T.J., L.C., L.A., C.Z., and S.W. carried out the tissue- and serum-based assays. C.S. and I.R. scored the immunohistochemistry assays. W.-C.C. and S.H. performed the bioinformatics and statistical analyses with supervision from F.M.B. and S.R.L. A.M.T., F.K., and M.P. provided advice on the design of the study and the analysis. S.R.L. wrote the manuscript with input from the other authors.</p>
              </sec>
              <sec id="sec5">
                <title>Declaration of Interests</title>
                <p id="p0265">The authors declare no competing interests.</p>
              </sec>
            </ack>
            <fn-group>
              <fn id="app1" fn-type="supplementary-material">
                <p id="p0270">Supplemental Information includes five figures and six tables and can be found with this article online at <ext-link ext-link-type="doi" xlink:href="10.1016/j.cmet.2018.08.021" id="intref0050">https://doi.org/10.1016/j.cmet.2018.08.021</ext-link>.</p>
              </fn>
            </fn-group>
          </back>
        </article>
      </metadata>
    </record>
  </GetRecord>
</OAI-PMH>
